[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3124
1. Fujiwara K, Nakahara C, Yamasaki T, Iwashita T: Adenocarcinoma of aberrant pancreas in the jejunum: report of a case. J Gastrointest Cancer; 2010 Jun;41(2):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of aberrant pancreas in the jejunum: report of a case.
  • INTRODUCTION: Aberrant pancreas in the jejunum is a rare condition, and its malignant transformation is very unusual.
  • CASE REPORT: We presented a case in which jejunal carcinoma occurred in the aberrant pancreas.
  • Histology showed that the tumor was made up of well-differentiated adenocarcinoma originating from aberrant pancreatic tissues.
  • CONCLUSION: This was the tenth case of aberrant pancreatic carcinoma in the jejunum reported in literature.
  • [MeSH-major] Adenocarcinoma / pathology. Choristoma. Jejunal Neoplasms / pathology. Pancreas. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Intestinal Obstruction / diagnosis. Intestinal Obstruction / etiology. Jejunal Diseases / pathology. Laparotomy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):504-7 [10228851.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Acta Chir Scand. 1988 Oct;154(10):599-601 [3213369.001]
  • (PMID = 19946765.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB: Intraoperative ultrasound of the pancreas. Ultrasound Q; 2009 Mar;25(1):39-48; quiz 48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasound of the pancreas.
  • Intraoperative ultrasound provides spatial resolution of the pancreas superior to computed tomography, magnetic resonance imaging, and transabdominal sonography.
  • This pictorial essay will review common benign and malignant pancreatic processes including the following: pancreatic ductal adenocarcinoma, pancreatitis, endocrine tumors, mucinous cystic neoplasm, intraductal papillary mucinous neoplasm, serous cystadenoma, and solid pseudopapillary tumor.
  • (1) identification of insulinoma(s) which are not detectable preoperatively, (2) identification of the pancreatic duct to determine dissection planes for chronic pancreatitis surgery (eg, Puestow procedure) and for tumor resection, and (3) staging purposes for malignant disease.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Diseases / surgery. Pancreatic Diseases / ultrasonography. Surgery, Computer-Assisted / methods. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276960.001).
  • [ISSN] 1536-0253
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


3. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol; 2007 Sep;31(3):567-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
  • The prognosis of advanced pancreatic cancer is poor.
  • We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro.
  • The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).
  • Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671683.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


Advertisement
4. Chang CL, Wu TC, Hung CF: Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther; 2007 Aug;14(16):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 [10779556.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Leukoc Biol. 2000 Dec;68(6):793-806 [11129646.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):859-63 [11221870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Vaccine. 2001 Nov 12;20(3-4):421-9 [11672905.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):356-60 [11676395.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3677-84 [11848542.001]
  • [Cites] Gene Ther. 2002 Feb;9(3):208-13 [11859424.001]
  • [Cites] Immunology. 2002 Sep;107(1):39-45 [12225361.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:d55-68 [12456324.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Nat Med. 2003 Jan;9(1):33-9 [12496961.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):976-83 [14601058.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] IDrugs. 2003 Dec;6(12):1155-64 [14666426.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Immunity. 1995 Aug;3(2):165-9 [7648389.001]
  • [Cites] Annu Rev Immunol. 1997;15:617-48 [9143702.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):89-94 [10728600.001]
  • (PMID = 17581599.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS321551; NLM/ PMC3182456
  •  go-up   go-down


5. Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA, Nguyen CC, Lake DF, Miller LJ: Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y); 2010 Apr;6(4):246-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for pancreatic adenocarcinoma and prospects for screening.
  • Pancreatic cancer has one of the worst survival rates of any cancer and is the fourth leading cause of cancer mortality.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Arch Intern Med. 1996 Oct 28;156(19):2255-60 [8885826.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):141-5 [8841182.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1996 Apr;6(2):379-407 [8673333.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):432-7 [8635856.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):975-7 [7666917.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):247-51 [7797022.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] JAMA. 1995 May 24-31;273(20):1605-9 [7745774.001]
  • [Cites] N Engl J Med. 1995 Feb 23;332(8):494-9 [7830730.001]
  • [Cites] Surg Radiol Anat. 1994;16(4):413-8 [7725198.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1510-6 [7932805.001]
  • [Cites] Radiology. 1994 Mar;190(3):745-51 [8115622.001]
  • [Cites] Pancreas. 1994 Jan;9(1):62-6 [8108373.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Radiology. 1992 Apr;183(1):87-95 [1312736.001]
  • [Cites] Pancreas. 1992;7(1):66-86 [1557348.001]
  • [Cites] Radiology. 1992 Mar;182(3):871-7 [1535911.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5501-3 [3308077.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] Radiology. 1982 Apr;143(1):129-33 [7063714.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4 Suppl):S82-6 [12297755.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3789-93 [12097290.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):249-54 [12020106.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):921-9 [11509056.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):682-707 [11179244.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Semin Surg Oncol. 2000 Jun;18(4):305-13 [10805952.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):786-91 [10570337.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Mar;7(3):259-69 [19121413.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):89-96 [19210116.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):299-307 [19150414.001]
  • [Cites] Fam Cancer. 2008;7(2):163-72 [17939062.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1653-66 [18025509.001]
  • [Cites] Pancreatology. 2007;7(5-6):514-25 [17912015.001]
  • [Cites] Acad Radiol. 2007 Jun;14(6):643-50 [17502253.001]
  • [Cites] Curr Gastroenterol Rep. 2007 Apr;9(2):130-5 [17418058.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):507-9 [17224924.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706 [17148771.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] J Comput Assist Tomogr. 2006 Jul-Aug;30(4):591-6 [16845289.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):253-83 [16549327.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1017-32, vii [15488555.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7 [15362797.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1188-95 [15083335.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1890-2 [15222030.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):99-111 [15238885.001]
  • [Cites] Med J Malaysia. 2003 Dec;58(5):667-72 [15190651.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1187-93 [15100116.001]
  • [Cites] Pancreas. 2004 Apr;28(3):273-8 [15084970.001]
  • [Cites] Pancreas. 2004 Apr;28(3):235-40 [15084963.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):798-804 [12910525.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):149-56 [12541123.001]
  • [Cites] Gastrointest Endosc. 2003 Jan;57(1):23-9 [12518126.001]
  • [Cites] J Proteome Res. 2009 Oct;8(10):4722-31 [19795908.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] J Magn Reson Imaging. 2009 Sep;30(3):586-95 [19711405.001]
  • [Cites] Top Magn Reson Imaging. 2009 Feb;20(1):3-9 [19687720.001]
  • [Cites] Pancreas. 2009 Jul;38(5):527-33 [19342980.001]
  • [Cites] J Am Coll Radiol. 2009 May;6(5):376-80 [19394581.001]
  • [Cites] Radiology. 2009 Apr;251(1):175-84 [19332852.001]
  • [Cites] Gut. 2006 Feb;55(2):252-8 [15972300.001]
  • [Cites] J Med Genet. 2005 Sep;42(9):711-9 [16141007.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):504-11 [16083707.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S46-8 [16012996.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2124-30 [15940643.001]
  • [Cites] World J Gastroenterol. 2005 Jun 28;11(24):3800-2 [15968744.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2076-83 [15886696.001]
  • [Cites] Dig Dis Sci. 2005 Apr;50(4):694-5 [15844704.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(5):359-65 [15764245.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10):753-63 [15545675.001]
  • [Cites] Gastroenterology. 1952 May;21(1):54-63 [14926813.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Radiology. 1999 Aug;212(2):445-52 [10429702.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):516-9 [10404064.001]
  • [Cites] Ann Surg. 1999 May;229(5):729-37; discussion 737-8 [10235532.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1253-60 [10235203.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1565-70 [9843289.001]
  • [Cites] Pancreas. 1998 Apr;16(3):396-401 [9548685.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):1-23 [9443984.001]
  • (PMID = 20567579.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886484
  • [Keywords] NOTNLM ; Pancreatic cancer / inherited risk factors / noninherited risk factors / screening
  •  go-up   go-down


6. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer; 2007 Apr 15;109(8):1561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
  • BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in pancreatic adenocarcinoma patients.
  • The presence of EGFR mutations and increased EGFR copy numbers in pancreatic adenocarcinoma was explored.
  • METHODS: Sixty-six pancreatic cancer patients were included in the analysis.
  • RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic pancreatic adenocarcinoma patients.
  • There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of diagnosis.
  • The EGFR amplification did not significantly influence survival in pancreatic adenocarcinoma patients (P = .935).
  • Thirty-two (49%) of the 65 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.
  • The presence of a point mutation in codon 12 adversely influenced survival of pancreatic cancer patients (P = .030).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics


7. Saif MW: Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP; 2009;10(4):373-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
  • Despite attempted curative resection of localized pancreatic adenocarcinoma, most patients succumb a recurrence and die of their disease.
  • The Gastrointestinal Tumor Study Group, European Organization for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer trials have suggested the benefit of adjuvant therapy.
  • This review will discuss the data available from reported trials of adjuvant therapy in pancreatic cancer, especially the results of the ESPAC-3 study presented at the annual meeting of ASCO 2009, and consider future directions for clinical trials.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy


8. Thakur V, Mukherjee U: Unusually high serum CA19.9 in gastric carcinoma: A case report. Indian J Clin Biochem; 2008 Jan;23(1):100-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of poorly differentiated adenocarcinoma of stomach, which did not present typical symptoms of gastrointestinal malignancy on first visit.
  • Histopathological examination of endoscopic biopsy revealed a poorly differentiated adenocarcinoma of stomach.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Clin Chim Acta. 1975 May 15;61(1):63-71 [1149250.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2036-41 [1544112.001]
  • [Cites] Int J Cancer. 1986 Nov 15;38(5):661-9 [2429934.001]
  • [Cites] Gut. 1987 Mar;28(3):323-9 [3471687.001]
  • [Cites] Cancer Detect Prev. 1985;8(1-2):181-7 [4064038.001]
  • [Cites] Jpn J Clin Oncol. 1999 Nov;29(11):550-5 [10678558.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):266-71 [11320518.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):105-9 [12488301.001]
  • (PMID = 23105733.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453653
  • [Keywords] NOTNLM ; CA 19.9 / CA72.4 / CEA / Gastric Carcinoma / Pancreas
  •  go-up   go-down


9. Morioka CY, Saito S, Machado MC, Jukemura J, Bacchella T, Watanabe A: Different pattern of metastasis in liver implanted pancreatic cancer between young and old Syrian golden hamsters. In Vivo; 2005 May-Jun;19(3):639-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pattern of metastasis in liver implanted pancreatic cancer between young and old Syrian golden hamsters.
  • We have previously reported on the "return trip" metastases from the liver to the pancreas in a hamster experimental pancreatic cancer model.
  • Because the pancreas is the main metastatic site of liver-implanted pancreatic tumors, our aim was to clarify whether the metastatic sites differ in young and old tumor-bearing animals.
  • HaP-T1, a continuous tissue-cultured cell line, derived from BHP-induced pancreatic adenocarcinoma, was implanted into the liver.
  • Animals of group A, sacrificed weekly until Day 70, showed metastases only to the pancreas ("return trip"), while this phenomenon happened only in animals sacrificed on Day 35 in group B.
  • In hamsters of group B, metastases were found in multiple sites such as the pancreas, vas deferens, ovary and testis ("multiple journeys").
  • [MeSH-major] Aging / physiology. Liver. Neoplasm Metastasis / physiopathology. Neoplasm Transplantation / methods. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875787.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Coban S, Ozkan H, Köklü S, Yüksel O, Koçkar MC, Akar T, Ormeci N: The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol; 2006 Sep;20(9):593-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among GI tract cancers, RCAS1 had lowest and highest sensitivity for esophagus and colon cancer diagnosis, respectively.
  • [MeSH-minor] Adenocarcinoma / immunology. Adult. Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Squamous Cell / immunology. Case-Control Studies. Colonic Neoplasms / immunology. Esophageal Neoplasms / immunology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity. Stomach Neoplasms / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74 [14571813.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):679-85 [12861064.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):310-5 [12845666.001]
  • [Cites] Pancreas. 2003 Jan;26(1):49-55 [12499917.001]
  • [Cites] Oncology. 2003;64(1):83-9 [12457035.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):101-5 [11809537.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):446-51 [11466701.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):197-202 [11403925.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):91-6 [11391627.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):488-93 [11102892.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1891-4 [14534714.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):805-20 [8960894.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • [Cites] Dig Liver Dis. 2004 Sep;36(9):622-7 [15460847.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):259-67 [15254686.001]
  • [Cites] Int J Hematol. 2004 May;79(4):340-4 [15218962.001]
  • [Cites] Cancer Sci. 2004 Mar;95(3):260-5 [15016327.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):4967-71 [14981953.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):559-63 [12971966.001]
  • (PMID = 17001401.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / EBAG9 protein, human
  • [Other-IDs] NLM/ PMC2659945
  •  go-up   go-down


11. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology; 2010;10(1):66-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
  • BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma.
  • METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).
  • CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(22):6773-84 [18794355.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Mol Diagn. 2008 Mar;10(2):111-22 [18258927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] PLoS One. 2008;3(7):e2557 [18596939.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]
  • [Cites] World J Surg. 2009 Apr;33(4):698-709 [19030927.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):1002-11 [19293812.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Pancreatology. 2009;9(1-2):66-72 [19077456.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3918-28 [19228262.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 [17520196.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Histopathology. 2007 Oct;51(4):539-46 [17714470.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1284-8 [17660710.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • (PMID = 20332664.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2865485
  •  go-up   go-down


12. Kindler HL, Aklilu M, Nattam S, Vokes EE: Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol; 2008 Dec;31(6):553-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
  • OBJECTIVES: There is no effective therapy for patients with metastatic pancreatic cancer who fail initial therapy with gemcitabine.
  • Arsenic trioxide has potent antiproliferative and proapoptotic effects in pancreatic cancer cell lines.
  • We conducted a multicenter phase II trial in patients with advanced pancreatic cancer who experienced disease progression on or after a gemcitabine-containing regimen.
  • CONCLUSIONS: Despite promising in vitro data, arsenic trioxide has no activity in pancreatic cancer patients who develop progressive disease after gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Deoxycytidine / analogs & derivatives. Oxides / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Resistance, Neoplasm. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060586.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-17102
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


13. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest; 2008 Feb;26(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  • BACKGROUND: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen.
  • There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer.
  • METHODS: Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.
  • CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181045.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, Goodchild K, Collis C, Bridgewater J: Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol (R Coll Radiol); 2010 Sep;22(7):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
  • AIMS: The optimal management for patients with unresectable locally advanced adenocarcinoma of the pancreas (LAPC) is unclear.
  • CONCLUSIONS: This is the largest reported series from the UK focussing on patients who received CRT for pancreas cancer.
  • It shows that it is possible to deliver pancreatic CRT with acceptable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20605709.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Pericleous S, Mukherjee S, Hutchins RR: Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature. World J Surg Oncol; 2008;6:120
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature.
  • BACKGROUND: Lung cancer is known to metastasize to the pancreas with several case reports found in the literature, however, most patients are at an advanced stage and receive palliative treatment.
  • Investigations revealed an obstructing lesion in the pancreas and a further lesion in the lung with benign appearances.
  • The patient underwent a pancreatectomy and, unexpectedly, the histology of the resected specimen demonstrated metastatic adenocarcinoma of bronchogenic origin.
  • We were unable to identify any previous case reports (of lung adenocarcinoma) with such a presentation which were ultimately treated with resection of both lesions.
  • CONCLUSION: Similar situations are bound to arise again in the future and we believe that this report could demonstrate that there is a case for aggressive surgical management in a highly selected group of patients: those with NSCLC and a synchronous solitary pancreatic deposit.
  • [MeSH-major] Adenocarcinoma / surgery. Jaundice, Obstructive / etiology. Lung Neoplasms / surgery. Pancreatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1993 Jul;104(1):98-100 [8391965.001]
  • [Cites] Gastroenterology. 1976 Jul;71(1):142-5 [1278639.001]
  • [Cites] Neoplasma. 1996;43(2):133-7 [8843976.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):413-7; discussion 418-9 [9565122.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2881-4 [9713480.001]
  • [Cites] J Korean Med Sci. 1999 Feb;14(1):107-9 [10102535.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Oct;28(10 Pt 1):872-6 [15523224.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Br J Cancer. 1955 Dec;9(4):511-27 [13304211.001]
  • [Cites] Pancreatology. 2004;4(6):509-20 [15316227.001]
  • [Cites] Tuberk Toraks. 2005;53(2):181-4 [16100657.001]
  • [Cites] Korean J Gastroenterol. 2005 Nov;46(5):409-12 [16301856.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2005 Dec;11(6):401-4 [16401990.001]
  • [Cites] Cancer. 2006 May 1;106(9):1998-2004 [16572401.001]
  • [Cites] J Gastrointestin Liver Dis. 2006 Mar;15(1):73-5 [16680238.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1536-42 [16847716.001]
  • [Cites] Korean J Intern Med. 2006 Jun;21(2):132-5 [16913445.001]
  • [Cites] Korean J Intern Med. 2006 Dec;21(4):256-61 [17249510.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):494-6 [17409905.001]
  • [Cites] Dig Liver Dis. 2008 Mar;40(3):230-1 [18096449.001]
  • [Cites] Chest. 2000 Mar;117(3):894-6 [10713023.001]
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):540-4 [10791233.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):663-6 [11569782.001]
  • [Cites] Acta Chir Belg. 2001 Jul-Aug;101(4):190-2 [11680063.001]
  • [Cites] Pathol Int. 2001 Sep;51(9):686-90 [11696171.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):337-9 [12009248.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):675-9 [12167582.001]
  • [Cites] Med Oncol. 2002;19(4):273-6 [12512922.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):97S-104S [12527569.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):292-7 [12908786.001]
  • [Cites] J Natl Med Assoc. 1980 Mar;72(3):215-20 [6248647.001]
  • [Cites] Ann Intern Med. 1985 Apr;102(4):487-90 [2983594.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):638-9 [2994535.001]
  • [Cites] Radiology. 1986 Aug;160(2):399-402 [3523591.001]
  • [Cites] Dig Dis Sci. 1987 Mar;32(3):327-31 [3028735.001]
  • [Cites] Dtsch Med Wochenschr. 1987 Aug 28;112(35):1335-7 [3622272.001]
  • [Cites] Eur J Surg Oncol. 1987 Aug;13(4):371-2 [3040475.001]
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • [Cites] Scott Med J. 1988 Dec;33(6):377 [2854301.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1990 Mar 15;65(6):1445-8 [2155057.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Dec;41(12):917-21 [14727556.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):99-111 [15238885.001]
  • [Cites] South Med J. 2004 Sep;97(9):811-5 [15455960.001]
  • [Cites] Med Welt. 1969 Feb 22;8:407-11 [5771340.001]
  • [Cites] Ann Thorac Surg. 1995 Dec;60(6):1609-11 [8787451.001]
  • (PMID = 19014447.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  • [Other-IDs] NLM/ PMC2615008
  •  go-up   go-down


16. Gulluoglu MG, Karayigit E, Ozden I, Kapran Y, Dizdaroglu F: Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer? Pathology; 2008 Jan;40(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
  • We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers.
  • The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).
  • METHODS: Sixty-five patients with PAC and DAPH who underwent pancreatic Whipple resection constituted the study cohort.
  • In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential diagnosis of PACs.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology. Diagnosis, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038313.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


17. Pappas S, Federle MP, Lokshin AE, Zeh HJ 3rd: Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am; 2007 Jun;36(2):413-29, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection and staging of adenocarcinoma of the pancreas.
  • Early diagnosis is likely to improve the outcome and survival in patients who have pancreatic cancer.
  • The sensitivity and specificity of current screening methods, however, limit their applicability to individuals at high risk for developing pancreatic cancer.
  • This article provides a review of current methods and results for the early detection and staging of pancreatic cancer, and discusses some potential areas for future development.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533087.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


18. Ringold DA, Yen RD, Chen YK: Direct dorsal pancreatoscopy with narrow-band imaging for the diagnosis of intraductal papillary mucinous neoplasm and pancreas divisum (with video). Gastrointest Endosc; 2010 Dec;72(6):1263-4; discussion 1264
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct dorsal pancreatoscopy with narrow-band imaging for the diagnosis of intraductal papillary mucinous neoplasm and pancreas divisum (with video).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Endoscopy, Digestive System / instrumentation. Image Enhancement / instrumentation. Pancreas / abnormalities. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Diabetes Mellitus, Type 1 / diagnosis. Diagnosis, Differential. Female. Humans. Pancreatic Ducts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20630512.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Video-Audio Media
  • [Publication-country] United States
  •  go-up   go-down


19. Marrache F, Tu SP, Bhagat G, Pendyala S, Osterreicher CH, Gordon S, Ramanathan V, Penz-Osterreicher M, Betz KS, Song Z, Wang TC: Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology; 2008 Oct;135(4):1277-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis.
  • BACKGROUND & AIMS: Chronic pancreatitis is a significant cause of morbidity and a known risk factor for pancreatic adenocarcinoma.
  • Interleukin-1beta is a proinflammatory cytokine involved in pancreatic inflammation.
  • We sought to determine whether targeted overexpression of interleukin-1beta in the pancreas could elicit localized inflammatory responses and chronic pancreatitis.
  • RESULTS: Three transgenic lines were generated, and in each line the pancreas was atrophic and occasionally showed dilation of pancreatic and biliary ducts secondary to proximal fibrotic stenosis.
  • Pancreatic histology showed typical features of chronic pancreatitis.
  • Older mice displayed acinar-ductal metaplasia but did not develop mouse pancreatic intraepithelial neoplasia or tumors.
  • CONCLUSIONS: Overexpression of interleukin-1beta in the murine pancreas induces chronic pancreatitis.
  • Elastase sshIL-1beta mice consistently develop severe chronic pancreatitis and constitute a promising model for studying chronic pancreatitis and its relationship with pancreatic adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:65-72 [16869739.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3147-60 [17114585.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1856-69 [17123526.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1557-73 [17466744.001]
  • [Cites] Dig Dis. 2007;25(3):282-4 [17827958.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):582-90 [10702210.001]
  • [Cites] Dig Dis Sci. 2000 Apr;45(4):665-74 [10759232.001]
  • [Cites] Diabetes. 2001 Jul;50(7):1553-61 [11423476.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1153-63 [11430819.001]
  • [Cites] JAMA. 2001 Jul 11;286(2):169-70 [11448279.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1105-12 [12016137.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):877-88 [12975454.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1481-93 [15039235.001]
  • [Cites] J Clin Invest. 2004 May;113(10):1398-407 [15146237.001]
  • [Cites] Am Rev Respir Dis. 1987 Jan;135(1):66-71 [2948432.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Arch Histol Cytol. 1995 Aug;58(3):365-74 [8527243.001]
  • [Cites] Cell Immunol. 1996 May 1;169(2):226-37 [8620550.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):231-6 [8661203.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1656-63 [9136845.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1664-72 [9136846.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2621-33 [9184209.001]
  • [Cites] Immunology. 1999 Jan;96(1):128-37 [10233687.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1587-95 [10359568.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Apr;32(4):311-8 [15668323.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • (PMID = 18789941.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093405; United States / NCI NIH HHS / CA / R01 CA120979-03; United States / NCI NIH HHS / CA / U54 CA126513; United States / NCI NIH HHS / CA / R01 CA093405-07A1; United States / NCI NIH HHS / CA / CA093405-07A1; United States / NCI NIH HHS / CA / CA120979-03; United States / NCI NIH HHS / CA / U54 CA126513-03; United States / NCI NIH HHS / CA / CA126513-03; United States / NCI NIH HHS / CA / R01 CA120979
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta; EC 3.4.21.36 / Pancreatic Elastase
  • [Other-IDs] NLM/ NIHMS73579; NLM/ PMC2707078
  •  go-up   go-down


20. Fukushima N, Mukai K: [Pathologic characteristics and evaluation of the pancreatic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):599-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic characteristics and evaluation of the pancreatic cancer].
  • Ductal adenocarcinoma is the most common tumor type of cancer of the pancreas.
  • It is generally a poorly demarcated, white to grey-solid tumor located in the pancreatic head.
  • Histologically, it is often well-to moderately-differentiated tubular adenocarcinoma along with marked desmoplastic change.
  • There are three well-defined precursors to invasive cancer; mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic intraepithelial neoplasia PanINs.
  • PanIN is now considered to be a precursor of pancreatic ductal adenocarcinoma based on molecular studies.
  • IPMNs and MCNs can form similar invasive carcinomas such as tubular adenocarcinoma and/or mucinous carcinoma.
  • Careful attention should be paid to the processes and/or criteria of pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / pathology. DNA-Binding Proteins / genetics. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Smad4 Protein. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918557.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators
  •  go-up   go-down


21. Limmathurotsakul D, Rerknimitr P, Korkij W, Noppakun N, Kullavanijaya P, Rerknimitr R: Metastatic mucinous cystic adenocarcinoma of the pancreas presenting as Sister Mary Joseph's nodule. JOP; 2007;8(3):344-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mucinous cystic adenocarcinoma of the pancreas presenting as Sister Mary Joseph's nodule.
  • CONTEXT: Sister Mary Joseph's nodule usually represents metastatic cancers from gastrointestinal malignancy including adenocarcinoma of the pancreas.
  • Mucinous cystadenocarcinoma is a rare malignancy of the pancreas.
  • However, pancreatic mucinous cystadenocarcinoma metastasized to Sister Mary Joseph's nodule is much rarer and has never been reported before.
  • A CT scan showed a large cystic lesion with internal septation at the pancreatic tail.
  • CONCLUSION: To our knowledge, this is the first report of pancreatic mucinous cystadenocarcinoma metastasized as Sister Mary Joseph's nodule.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Pancreatic Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495365.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


22. Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG, Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin V, Strate T, Izbicki JR: Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis. Anticancer Res; 2007 Jan-Feb;27(1A):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.
  • Kazal-type genes are associated with cancer and pancreatic disease.
  • The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with pancreatic carcinoma and chronic pancreatitis.
  • MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with pancreatic adenocarcinoma and 117 with chronic pancreatitis.
  • RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in pancreatic carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.
  • No correlation in frequency of STRs comparing chronic pancreatitis and pancreatic cancer was determined using the Chi-squared test (p = 0.23).
  • CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in pancreatic adenocarcinoma and chronic pancreatitis detected in peripheral blood.
  • None of the polymorphisms was associated with poor clinical outcome in pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352218.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


23. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R: Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park); 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
  • In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients.
  • Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247017.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


24. Shtilbans V, Wu M, Burstein DE: Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol; 2008 Apr;12(2):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following review summarizes the use of phospho-AKT immunohistochemistry as a potentially valuable tool in cancer prognostication in a wide spectrum of common and uncommon malignancies, including squamous carcinoma of cervix and of head and neck; adenocarcinoma of endometrium, ovarian, breast, prostate, kidney, colon, and pancreas; carcinomas of lung and thyroid; and hematopoietic, soft tissue, and central nervous system neoplasms.
  • To date, the findings overall suggest that the major use of p-AKT immunohistochemical staining lies in prognostication and possibly in individualization of therapy rather than in differential diagnosis.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325479.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Number-of-references] 79
  •  go-up   go-down


25. Sceusi EL, Wray CJ: Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence. World J Surg Oncol; 2009;7:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.
  • BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with pancreatic adenocarcinoma.
  • Pancreatic resection in these patients has rarely been described.
  • CT scan imaging is a principle modality for detecting pancreatic cancer and its use in SI patients is seldom reported.
  • CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a pancreatic head mass requiring a pancreaticoduodenectomy.
  • The surgical pathology report demonstrated pancreatic adenocarcinoma.
  • CONCLUSION: SI is a rare condition with concurrent pancreatic cancer being even rarer.
  • Additionally, radiographic imaging has significantly improved detection of early pancreatic cancer; however, there continues to be a need for improved detection of small neoplasms.
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Situs Inversus / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2009 Oct;19(10):2448-55 [19415290.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8 [18948228.001]
  • [Cites] Transplant Proc. 2008 Jun;40(5):1792-5 [18589199.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):524-7 [17081721.001]
  • [Cites] Wiad Lek. 2006;59(9-10):707-9 [17338134.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):512-9 [16891882.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Semin Cell Dev Biol. 1998 Feb;9(1):89-99 [9572118.001]
  • [Cites] J Clin Gastroenterol. 1997 Mar;24(2):92-6 [9077725.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):897-903 [15039161.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):606-7 [12781900.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1263-72 [12479710.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Am J Med Genet. 2001 Jul 15;101(4):345-55 [11471158.001]
  • [Cites] Surg Radiol Anat. 2000;22(5-6):293-7 [11236325.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]
  • (PMID = 20021643.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803176
  •  go-up   go-down


26. Morse DL, Balagurunathan Y, Hostetter G, Trissal M, Tafreshi NK, Burke N, Lloyd M, Enkemann S, Coppola D, Hruby VJ, Gillies RJ, Han H: Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol; 2010 Sep 1;80(5):748-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.
  • Pancreatic cancer has a high mortality rate, which is generally related to the initial diagnosis coming at late stage disease combined with a lack of effective treatment options.
  • Novel agents that selectively detect pancreatic cancer have potential for use in the molecular imaging of cancer, allowing for non-invasive determination of tumor therapeutic response and molecular characterization of the disease.
  • Using complementary assays of mRNA expression profiling to determine elevated expression in pancreatic cancer tissues relative to normal pancreas tissues, and validation of protein expression by immunohistochemistry on tissue microarray, we have identified cell-surface targets with potential for imaging and therapeutic agent development.
  • Expression profiles of 2177 cell-surface genes for 28 pancreatic tumor specimens and 4 normal pancreas tissue samples were evaluated.
  • One-hundred seventy unique targets were highly expressed in 2 or more of the pancreatic tumor specimens and were not expressed in the normal pancreas samples.
  • These validated targets have potential for the development of diagnostic imaging and therapeutic agents for pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Stem Cells Dev. 2010 Sep;19(9):1333-41 [20132051.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1256-60 [11888886.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39822-9 [12860988.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:141S-50S [15653662.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Mar;5(2):171-81 [15833047.001]
  • [Cites] Anal Biochem. 2005 Jul 1;342(1):69-77 [15958182.001]
  • [Cites] Drug Resist Updat. 2005 Dec;8(6):381-402 [16309948.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Apr;8(3):280-91 [18393787.001]
  • [Cites] Oncologist. 2008 May;13(5):562-76 [18515741.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5380-9 [18593940.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):3071-80 [18765825.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):280-7 [18813195.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:169-80 [18837898.001]
  • [Cites] J Med Chem. 2009 Jan 8;52(1):126-33 [19055415.001]
  • [Cites] Cancer Sci. 2009 Apr;100(4):572-9 [19462526.001]
  • [Cites] JOP. 2009;10(4):352-6 [19581733.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2356-65 [19671749.001]
  • [Cites] Nanotechnology. 2009 Sep 30;20(39):395102 [19726840.001]
  • [Cites] Photochem Photobiol. 2009 Sep-Oct;85(5):1053-74 [19682322.001]
  • [Cites] FASEB J. 2010 Feb;24(2):514-25 [19843711.001]
  • [Cites] Surg Oncol Clin N Am. 2010 Apr;19(2):431-51 [20159524.001]
  • [Cites] Curr Pharm Des. 2010;16(9):1040-54 [20030617.001]
  • [Cites] Curr Pharm Des. 2010;16(9):1081-90 [20030618.001]
  • [Cites] J Control Release. 2010 Aug 3;145(3):182-95 [20226220.001]
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • (PMID = 20510208.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123547-03; United States / NCI NIH HHS / CA / CA123547; United States / NCI NIH HHS / CA / CA097360; United States / NCI NIH HHS / CA / R01 CA123547; United States / NCI NIH HHS / CA / R01 CA097360; United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / CA123547-03; United States / NCI NIH HHS / CA / P01 CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / CA109552; United States / NCI NIH HHS / CA / R01 CA097360-05A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS208520; NLM/ PMC2914681
  •  go-up   go-down


27. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E: Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma; 2009;56(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
  • The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers.
  • We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers.
  • -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases.
  • Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.
  • [MeSH-major] Adenocarcinoma / genetics. Interferon-gamma / genetics. Pancreatic Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


28. Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G: Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma. Tumori; 2010 May-Jun;96(3):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
  • AIMS AND BACKGROUND: Gemcitabine is an effective agent in pancreatic adenocarcinoma.
  • We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
  • METHODS: Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845800.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


29. Janssen PJ, de Visser M, Verwijnen SM, Bernard BF, Srinivasan A, Erion JL, Breeman WA, Vulto AG, Krenning EP, de Jong M: Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors. Cancer Biother Radiopharm; 2007 Jun;22(3):374-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurotensin (NT) receptors are overexpressed in different human tumors, such as human ductal pancreatic adenocarcinoma.
  • The aim of this study was to explore the biodistribution, tumor uptake, kidney localization, and stability characteristics of these new analogs in order to develop new diagnostic tools for exocrine pancreatic cancer.
  • In the biodistribution study in mice, at 4 hours postinjection, a low percentage of the injected dose per gram (%ID/g) of tissue for all compounds was found in NT receptor-negative organs, such as the blood, spleen, pancreas, liver, muscle, and femur.

  • Hazardous Substances Data Bank. L-Lysine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651043.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Oligopeptides; 39379-15-2 / Neurotensin; 7A314HQM0I / Pentetic Acid; K3Z4F929H6 / Lysine
  •  go-up   go-down


30. Sakpal SV, Sexcius L, Babel N, Chamberlain RS: Agenesis of the dorsal pancreas and its association with pancreatic tumors. Pancreas; 2009 May;38(4):367-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agenesis of the dorsal pancreas and its association with pancreatic tumors.
  • Morphogenesis of the pancreas is a complex process; nevertheless, congenital anomalies are rare.
  • At embryogenesis, the pancreas develops from the endoderm-lined dorsal and ventral buds of the duodenum.
  • The ventral bud gives rise to the lower head and uncinate process of the pancreas; whereas, the dorsal bud gives rise to the upper head, isthmus, body, and tail of the pancreas.
  • Rarely, developmental failure of the dorsal pancreatic bud at embryogenesis results in the agenesis of the dorsal pancreas--neck, body, and tail.
  • Even rarer is the association of pancreatic tumors with agenesis of the dorsal pancreas.
  • In addition to citing our case, we provide a comprehensive review on agenesis of the dorsal pancreas and its association with pancreatic tumors.
  • [MeSH-major] Pancreas / abnormalities. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed


31. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol; 2008 Jul 20;26(21):3511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
  • PURPOSE: To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma.
  • PATIENTS AND METHODS: We performed a retrospective review 472 consecutive patients who underwent complete resection with negative margins (R0) for invasive carcinoma (T1-3N0-1M0) of the pancreas between 1975 and 2005 at the Mayo Clinic in Rochester, MN.
  • Tumor extension beyond the pancreas was an adverse prognostic factor by univariate analysis alone (P = .03).
  • CONCLUSION: This study represents one of the largest, single-institution, retrospective reviews of adjuvant therapy in patients after R0 resection of carcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Adjuvant. Pancreatic Neoplasms / therapy. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jul 20;26(21):3478-80 [18640927.001]
  • (PMID = 18640932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Macari M, Eubig J, Robinson E, Megibow A, Newman E, Babb J, Pachter HL, Hajdu C: Frequency of intraductal papillary mucinous neoplasm in patients with and without pancreas cancer. Pancreatology; 2010;10(6):734-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of intraductal papillary mucinous neoplasm in patients with and without pancreas cancer.
  • PURPOSE: To determine the frequency of intraductal papillary mucinous neoplasm (IPMN) in patients with and without invasive ductal adenocarcinoma (IDAC).
  • METHODS: 82 patients underwent pancreatectomy for pancreas adenocarcinoma.
  • Fisher's exact test was used to test whether the prevalence of IPMN was greater among patients with pancreas cancer than those without.
  • RESULTS: Five of 68 (7.3%) patients who underwent pancreatic resection for IDAC had IPMN at a site distant from the cancer.
  • The odds ratio for IPMN as a predictor of pancreas cancer was estimated as 7.18.
  • CONCLUSION: IPMN occurs with increased frequency in patients with pancreas cancer as opposed to those without pancreas cancer. and IAP.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreas / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. New York / epidemiology. Pancreatic Neoplasms. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21252588.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ: Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg; 2009 Apr;33(4):716-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
  • BACKGROUND: Timely, accurate diagnosis of pancreatic adenocarcinoma (PA) is hampered by the lack of effective circulating biomarkers.
  • The goals of this study were to validate two acute-phase proteins, haptoglobin and serum amyloid A (SAA), as biomarkers for PA and determine if the combination of haptoglobin, SAA, and CA 19-9 would improve PA diagnosis over CA 19-9 alone.
  • METHODS: Levels of haptoglobin, SAA, and CA 19-9 were measured in pretreatment sera from 75 PA patients, 32 patients with chronic pancreatitis, 42 patients with other benign pancreatic disease or biliary stricture, and 150 healthy control subjects by enzyme-linked immunosorbent assay or colorimetric binding assay.
  • This study supports the use of combined biomarkers for improved accuracy in the diagnosis of PA.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Pharm Bull (Tokyo). 1992 Jul;40(7):1847-51 [1394703.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Sep;35(9):647-54 [9352226.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):93-101 [9443988.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):109-12 [9488584.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9 [10065510.001]
  • [Cites] Eur J Biochem. 1999 Oct;265(2):501-23 [10504381.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):442-6 [16428484.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):84-93 [17063306.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):629-35 [17303689.001]
  • [Cites] Pancreas. 2007 Apr;34(3):310-7 [17414053.001]
  • [Cites] Pancreas. 2007 May;34(4):436-43 [17446843.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):886-91 [17507610.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1774(6):764-71 [17507299.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):129-33 [11341746.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2145-51 [11448934.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1123-5 [12039846.001]
  • [Cites] Int J Exp Pathol. 2003 Apr;84(2):69-74 [12801280.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):681-91 [12888904.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1720-4 [12973732.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1031-8 [15154618.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):845-56 [15107802.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):379-84 [15241837.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5293; author reply 5293-4 [15297433.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Biochim Biophys Acta. 1987 Feb 14;917(2):219-23 [2879568.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):462-8 [3162513.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] Pancreatology. 2007;7(5-6):526-30 [17901713.001]
  • [Cites] J Clin Invest. 1993 Mar;91(3):977-85 [7680672.001]
  • (PMID = 19082654.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115225-02; United States / NCI NIH HHS / CA / R01 CA115225; United States / NCI NIH HHS / CA / R03 CA115225-02; United States / NCI NIH HHS / CA / P30CA042014; United States / NCI NIH HHS / CA / R13 CA132572; United States / NCI NIH HHS / CA / R03 CA115225; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Haptoglobins; 0 / Serum Amyloid A Protein
  • [Other-IDs] NLM/ NIHMS93122; NLM/ PMC2656575
  •  go-up   go-down


34. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, Dennison AR, Berry DP: Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg; 2008 Jun;12(6):1068-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
  • Despite extensive preoperative staging, a significant number of pancreatic cancers are unresectable at surgical exploration.
  • Patients undergoing pancreatic exploration with a view to resection were studied and comparisons are then made between those undergoing resection and a bypass procedure to identify surrogate markers of unresectability.
  • One hundred thirteen consecutive patients underwent pancreatic exploration for head-of-pancreas (HOP) adenocarcinoma with curative intent.
  • A significant proportion of patients with HOP adenocarcinoma are understaged preoperatively.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Decision Making. Pancreatic Neoplasms / blood. Pancreaticoduodenectomy / methods. Urea / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2006 Mar;99(3):306-8 [16553110.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):492-501 [15056091.001]
  • [Cites] Surg Oncol. 2005 Aug;14 (2):105-13 [16125619.001]
  • [Cites] Int J Surg. 2007 Feb;5(1):27-30 [17386911.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):350-6 [17458610.001]
  • [Cites] Am J Surg. 2005 Mar;189(3):278-82 [15792750.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):431-8 [17180286.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1286-92 [16332484.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):181-4 [16118772.001]
  • [Cites] Eur J Surg Oncol. 2007 Sep;33(7):892-7 [17398060.001]
  • [Cites] Can J Surg. 2006 Aug;49(4):241-4 [16948881.001]
  • [Cites] JOP. 2005 Nov 10;6(6):552-61 [16286705.001]
  • [Cites] Pancreas. 2004 Aug;29(2):132-40 [15257105.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):350-5 [1348409.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1493-8 [11677994.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):951-5; discussion 955-6 [12963650.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4A):2449-56 [11724306.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(5):435-41 [17013719.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):9-17 [11141219.001]
  • (PMID = 18043987.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 8W8T17847W / Urea
  •  go-up   go-down


35. Freitas D, Fernandes Gdos S, Hoff PM, Cunha JE: Medical management of pancreatic adenocarcinoma. Pancreatology; 2009;9(3):223-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of pancreatic adenocarcinoma.
  • Pancreatic cancer is the fourth leading cause of cancer death in the United States.
  • In 2008, an estimated 34,290 people died from pancreatic cancer and 37,680 new cases were diagnosed.
  • Despite modern treatment, 90% of patients die within 1 year of diagnosis.
  • In the present paper the English-language literature addressing the medical management in pancreatic cancer was reviewed.
  • Based on these data we will discuss the role of currently used chemotherapy and target therapy in pancreatic cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19420981.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


36. Donadelli M, Dalla Pozza E, Costanzo C, Scupoli MT, Scarpa A, Palmieri M: Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. J Cell Biochem; 2008 May 1;104(1):202-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
  • We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce pancreatic cancer cell viability.
  • TPEN was much more efficient to inhibit pancreatic adenocarcinoma cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer.
  • Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on pancreatic cancer cells than on normal primary fibroblasts.
  • This effect may be explained by a significantly higher zinc depletion by TPEN in pancreatic cancer cells as compared to fibroblasts.
  • In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of pancreatic cancer because of its reduced antiproliferative effect on normal cells.
  • [MeSH-major] Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / therapy. Zinc / deficiency

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979179.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc
  •  go-up   go-down


37. Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, Lillemoe KD: Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg; 2009 May;208(5):989-94; discussion 994-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer.
  • Clinical and basic studies have shown obesity to be associated with an increased incidence and progression of pancreatic cancer.
  • The precise role that pancreatic fat plays in this process has remained undefined.
  • We tested the hypothesis that pancreatic steatosis would be associated with increased dissemination and reduced survival in patients with resected pancreatic cancer.
  • STUDY DESIGN: A case-control analysis was conducted in patients who had undergone resection for pancreatic adenocarcinoma.
  • Pancreatic neck margins were reviewed in a blinded fashion by two trained investigators.
  • Pancreatic fat (number of cells/5 high power field) and degree of fibrosis (0 to 4+) were recorded.
  • RESULTS: Node-positive patients had significantly more fat cells in the pancreas compared with node-negative patients (46.4 +/- 8.7 versus 21.4 +/- 4.8; p < 0.02).
  • CONCLUSIONS: These data show that increased pancreatic fat promotes dissemination and lethality of pancreatic cancer.
  • We conclude that pancreatic steatosis alters the tumor microenvironment, enhances tumor spread, and contributes to the early demise of patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adipose Tissue / pathology. Pancreas / pathology. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology


38. Glowka TR, Kalff JC, Pantelis D, Hirner A, Standop J: Secondary surgery subsequent to distal pancreatectomy. Hepatogastroenterology; 2010 Jul-Aug;57(101):952-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Early revision procedures after pancreatic head resection significantly increase mortality.
  • We sought to critically analyze indications and outcome from early revision and subsequent redo procedures following distal pancreatic resection (DPR).
  • METHODOLOGY: During a 5-year period 53 subsequent patients undergoing DPR were identified from a pancreatic resection database and analyzed regarding indication for and outcome of early revision and late redo procedures.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreatitis, Chronic / surgery
  • [MeSH-minor] Abdominal Injuries / radiography. Female. Humans. Length of Stay. Male. Pancreas / injuries. Reoperation. Splenectomy. Tomography, X-Ray Computed. Wounds, Nonpenetrating / radiography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033258.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N: Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas; 2006 Apr;32(3):281-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.
  • OBJECTIVES: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is an indolent neoplasm by nature; however, it sometimes acquires invasive potential and has been classified as invasive IPMN.
  • The aim of the present study was to investigate the clinicopathologic difference between invasive IPMN and a common type of invasive ductal carcinoma of the pancreas.
  • The resulting data were compared with those of 274 patients with a common type of pancreatic ductal carcinoma who underwent surgery during the same period.
  • CONCLUSIONS: An increased awareness of invasive IPMN has enabled pancreatectomies to be performed at an earlier stage, relative to that for ordinary pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628084.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Martignoni ME, Kunze P, Hildebrandt W, Künzli B, Berberat P, Giese T, Klöters O, Hammer J, Büchler MW, Giese NA, Friess H: Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res; 2005 Aug 15;11(16):5802-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia.
  • BACKGROUND AND PURPOSE: The mechanism behind aggressive development of cachexia in patients suffering from pancreatic cancer is not well understood.
  • EXPERIMENTAL DESIGN: DNA microarray analysis and quantitative reverse transcription-PCR were used to screen for cachexia-associated factors in pancreatic specimens obtained from noncachectic and cachetic patients diagnosed with pancreatic ductal adenocarcinoma.
  • The expression pattern of the most prominently altered cachexia-associated factor, interleukin-6 (IL-6), was further analyzed in patients sera by ELISA, in pancreatic specimens by immunohistochemistry, and in a coculture system by quantitative reverse transcription-PCR using pancreatic cancer cell lines T3M4 (IL-6 positive) and Panc-1 (IL-6 negative) and peripheral blood mononuclear cells (PBMC) obtained from donors and noncachectic and cachectic patients.
  • RESULTS: Among numerous analyzed factors, IL-6 was significantly overexpressed in pancreatic specimens and elevated in serum of cachectic patients.
  • The coculture system revealed that pancreatic cancer T3M4 cells but not Panc-1 cells were able to stimulate IL-6 exclusively in cachectic PBMC (by 14-fold) and this triggering was reduced by half in the presence of IL-6-neutralizing antibodies.
  • CONCLUSION: IL-6 represents a prominent cachexia-associated factor in pancreatic cancer.
  • [MeSH-major] Cachexia / genetics. Interleukin-6 / genetics. Leukocytes, Mononuclear / metabolism. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Chronic Disease. Coculture Techniques. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Pancreas / metabolism. Pancreatitis / genetics. Pancreatitis / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115919.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger
  •  go-up   go-down


41. Adams RB, Allen PJ: Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. Ann Surg Oncol; 2009 Jul;16(7):1745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreas / pathology. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg Oncol. 2009 Jul;16(7):1736-44 [19387741.001]
  • (PMID = 19396494.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia; 2006 Apr;8(4):279-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
  • The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31).
  • Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1999 Nov-Dec;60(6):544-8 [10545724.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):285-302 [16012954.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6776-84 [10597286.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] J Med Invest. 2000 Feb;47(1-2):47-55 [10740979.001]
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3245-9 [11309273.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52 [11467451.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):328-37 [15893416.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4127-34 [11911306.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2015-27 [12174879.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844 [12504222.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):202-16 [12512043.001]
  • [Cites] J Pathol. 2003 Feb;199(2):185-90 [12533831.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:199-231 [12195027.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):586-92 [12566300.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5 [12642683.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):161-70 [12706873.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):328-35 [12791299.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97 [12849999.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1134-46 [15057752.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Trends Genet. 1993 Sep;9(9):317-21 [8236461.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):177-84 [7824270.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):431-6 [10201374.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):504-11 [10404062.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1253-6 [10523691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):132-41 [15893845.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • (PMID = 16756720.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC1600679
  •  go-up   go-down


43. Yango J, Pieters T, Coche E, Lambert M: [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir; 2008 Jan;25(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Elévation du CA 19.9 sérique et bronchectasies.
  • INTRODUCTION: CA 19.9 is considered the most specific and sensitive serological marker of pancreatic adenocarcinoma.
  • Exhaustive investigation and clinical evolution excluded a neoplastic digestive disorder but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
  • [MeSH-major] Bronchiectasis / diagnosis. CA-19-9 Antigen / blood
  • [MeSH-minor] Aged. Biomarkers / blood. Female. Haemophilus Infections / diagnosis. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans

  • Genetic Alliance. consumer health - Bronchiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288056.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


44. Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett; 2006 Feb 28;233(2):328-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
  • Pancreatic cancers express KIT and PDGFRs.
  • Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily.
  • Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens.
  • In this small series of pancreatic cancer patients, treatment with imatinib was not associated with a significant control of cancer progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Benzamides. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Quality of Life. Receptors, Platelet-Derived Growth Factor / metabolism. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893416.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


45. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR: Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res; 2010 Mar 1;70(5):2064-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
  • Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, with an overall 5-year survival rate of <5%.
  • Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is highly resistant to conventional chemotherapies, underscoring the critical need for new molecular targets for pancreatic cancer chemotherapy.
  • However, little is known about the role of PKCiota in pancreatic cancer.
  • In this study, we evaluated the expression of PKCiota in human pancreatic cancer and the requirement for PKCiota for the transformed growth and tumorigenicity of PDAC cells.
  • We find that PKCiota is significantly overexpressed in human pancreatic cancer, and high PKCiota expression correlates with poor patient survival.
  • Inhibition of PKCiota expression in pancreatic tumors also significantly reduces tumor angiogenesis and metastasis.
  • Taken together, our data show a required role for PKCiota in the transformed growth of pancreatic cancer cells and reveal a novel role for PKCiota in pancreatic cancer cell metastasis and angiogenesis in vivo.
  • Our results strongly indicate that PKCiota will be an effective target for pancreatic cancer therapy.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11557-65 [9111071.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] J Cell Biol. 1999 Feb 8;144(3):413-25 [9971737.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31109-15 [15994303.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8905-11 [16204062.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):235-41 [16397047.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1767-74 [16452237.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2403-13 [16489047.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4627-35 [16651413.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):933-9 [16788754.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28450-9 [16861740.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8 [17062694.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3853-61 [17440100.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3527-33 [17879119.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):110-9 [18175225.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2462-70 [18271008.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5888-95 [18632643.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4841-53 [18427549.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7403-8 [18794128.001]
  • [Cites] Pancreatology. 2008;8(6):587-92 [18849640.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1643-50 [19221092.001]
  • [Cites] Cell Prolif. 2009 Apr;42(2):182-94 [19243387.001]
  • [Cites] Microvasc Res. 2009 Jun;78(1):40-4 [19327373.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7603-11 [19738040.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2880-9 [10733591.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):496-504 [11169932.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42834-42 [11551901.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):915-20 [12058013.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2379-87 [12750255.001]
  • [Cites] Cancer Control. 2004 Jan-Feb;11(1):32-8 [14749621.001]
  • [Cites] J Cell Biol. 2004 Mar 15;164(6):797-802 [15024028.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3327-32 [15161686.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):100-12 [15305381.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35604-15 [15155749.001]
  • [Cites] Pancreas. 2004 Oct;29(3):193-203 [15367885.001]
  • [Cites] Mol Carcinog. 1997 Oct;20(2):251-8 [9364215.001]
  • (PMID = 20179210.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA081436; United States / NCI NIH HHS / CA / R01 CA081436-12; United States / NCI NIH HHS / CA / CA081436-12; United States / NCI NIH HHS / CA / CA128661; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / R21 CA128661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Messenger; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.6.5.2 / rac1 GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS170593; NLM/ PMC2881466
  •  go-up   go-down


46. Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA: Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res; 2010 Dec 1;16(23):5712-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
  • PURPOSE: Pancreatic carcinoma is one of the deadliest cancers with few effective treatments.
  • We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human pancreatic xenograft destruction in a murine model.
  • EXPERIMENTAL DESIGN: Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively.
  • Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field-induced destruction of Panc-1 and Capan-1 pancreatic carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S [14506191.001]
  • [Cites] J Biomed Opt. 2000 Oct;5(4):383-90 [11092426.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2245-51 [445424.001]
  • [Cites] Ann Clin Lab Sci. 1981 Sep-Oct;11(5):386-91 [7036839.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9 [2106751.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1271-86 [8863675.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Lasers Surg Med. 1998;23(4):194-203 [9829430.001]
  • [Cites] Langmuir. 2005 Nov 8;21(23):10644-54 [16262332.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2654-65 [17960610.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] Nat Protoc. 2008;3(2):314-20 [18274533.001]
  • [Cites] Biophys J. 2008 May 15;94(10):3790-7 [18234813.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Surgery. 2008 Aug;144(2):125-32 [18656617.001]
  • [Cites] J Exp Ther Oncol. 2008;7(4):313-26 [19227011.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] World J Gastroenterol. 2009 Jun 28;15(24):2995-3002 [19554652.001]
  • [Cites] Small. 2009 Jul;5(13):1553-61 [19326357.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Radiat Biol. 2009 Dec;85(12):1114-25 [19995237.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45 [19909777.001]
  • [Cites] J Surg Oncol. 2010 Mar 15;101(4):315-20 [20187063.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 May 15;245(1):116-23 [20193702.001]
  • [Cites] Cancer. 2010 Jul 1;116(13):3285-93 [20564640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • (PMID = 21138869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA151668-02; United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / U54 CA151668; United States / NCI NIH HHS / CA / T32 CA009599-21; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / U54 CA151668-02; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 7440-57-5 / Gold; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS245136; NLM/ PMC3057504
  •  go-up   go-down


47. Ishii H, Furuse J, Nakachi K, Suzuki E, Yoshino M: Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. Jpn J Clin Oncol; 2005 Oct;35(10):601-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials.
  • BACKGROUND: It is unclear whether primary pancreatic cancer (PC) tumors can be accepted as measurable target lesions in chemotherapy trials.
  • METHODS: The patient selection criteria were (i) having been admitted between January 2002 and December 2004, (ii) diagnosed as having histologically or cytologically proven adenocarcinoma of the pancreas, (iii) treated with chemotherapy with no previous anticancer treatment and (iv) having been evaluated by follow-up CT to assess the response according to the Response Evaluation Criteria in Solid Tumors criteria.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology


48. Wada K, Takada T, Amano H, Yoshida M, Miura F, Toyota N, Kato K, Isaka T, Nagashima I: [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe].
  • Pancreatic adenocarcinoma remains to have poor prognosis.
  • Current rationale for the treatment of pancreatic adenocarcinoma in the US and European countries consists of the following formula:.
  • The efficacy of "Japanese" radical resection including vascular resection or pancreatic nerve plexus resection should be evaluated, although the devise of novel diagnostic modalities and more effective adjuvant or neoadjuvant therapy are crucial to improve prognosis of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878412.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


49. Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM: Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol; 2009 Jul 1;100(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
  • BACKGROUND: There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics, prognosis, and outcome.
  • RESULTS: One hundred thirty-six cases of PAC, age <or=45 years at diagnosis, were identified.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19384918.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Furukawa H, Uesaka K, Boku N: Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography. Arch Surg; 2008 Mar;143(3):275-80; discussion 281
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography.
  • HYPOTHESIS: Multidetector-row computed tomography reduces the frequency of use of other imaging methods in patients with pancreatic carcinoma.
  • PATIENTS: Two hundred thirteen patients with pancreatic carcinoma.
  • MAIN OUTCOME MEASURE: Multidetector-row computed tomography was initially performed in patients with newly diagnosed pancreatic carcinoma.
  • RESULTS: Of the 213 pancreatic carcinomas, 79 (37%) were classified as probably resectable, 127 (60%) as certainly unresectable, and 7 (3%) as probably unresectable.
  • CONCLUSIONS: Multidetector-row computed tomography provides reliable information for staging pancreatic carcinoma.
  • Multidisciplinary team discussion along with use of this noninvasive technique simplifies the diagnostic strategy for pancreatic carcinoma and decreases the need for invasive staging methods.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / radiography. Decision Making. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347275.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Săftoiu A, Vilmann P, Gorunescu F, Gheonea DI, Gorunescu M, Ciurea T, Popescu GL, Iordache A, Hassan H, Iordache S: Neural network analysis of dynamic sequences of EUS elastography used for the differential diagnosis of chronic pancreatitis and pancreatic cancer. Gastrointest Endosc; 2008 Dec;68(6):1086-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neural network analysis of dynamic sequences of EUS elastography used for the differential diagnosis of chronic pancreatitis and pancreatic cancer.
  • OBJECTIVE: To assess the accuracy of real-time EUS elastography in pancreatic lesions.
  • PATIENTS: The study group included, in total, 68 patients with normal pancreas (N = 22), chronic pancreatitis (N = 11), pancreatic adenocarcinoma (N = 32), and pancreatic neuroendocrine tumors (N = 3).
  • A subgroup analysis of 43 cases with focal pancreatic masses was also performed.
  • MAIN OUTCOME MEASUREMENTS: To differentiate normal pancreas, chronic pancreatitis, pancreatic cancer, and neuroendocrine tumors.
  • CONCLUSIONS: EUS elastography is a promising method that allows characterization and differentiation of normal pancreas, chronic pancreatitis, and pancreatic cancer.
  • The currently developed methodology, based on artificial neural network processing of EUS elastography digitalized movies, enabled an optimal prediction of the types of pancreatic lesions.
  • Future multicentric, randomized studies with adequate power will have to establish the clinical impact of this procedure for the differential diagnosis of focal pancreatic masses.
  • [MeSH-major] Elasticity Imaging Techniques / methods. Endosonography. Neural Networks (Computer). Pancreatic Neoplasms / ultrasonography. Pancreatitis, Chronic / ultrasonography
  • [MeSH-minor] Cross-Sectional Studies. Diagnosis, Differential. Feasibility Studies. Female. Humans. Male. Middle Aged. Prospective Studies


52. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD: Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One; 2007 Apr 25;2(4):e392
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
  • Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma.
  • PRINCIPLE FINDINGS: Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines.
  • Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling.
  • Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth.
  • CONCLUSIONS/SIGNIFICANCE: We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells.
  • Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] Genes Cells. 2002 Feb;7(2):173-85 [11895481.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5 [15240889.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6170-4 [15208662.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):653-61 [15352211.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] Development. 2004 Dec;131(24):6009-21 [15563523.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):743-8 [15705870.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6245-54 [16024626.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] Dev Dyn. 2006 Mar;235(3):681-90 [16425220.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4969-76 [16377625.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2130-44 [16762634.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6025-32 [16778174.001]
  • [Cites] Biochem J. 2006 Nov 15;400(1):63-73 [16901266.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):678-88 [17116694.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):169-73 [11457867.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):357-61 [11489926.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30744-52 [11406624.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1663-6 [11533491.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):293-7 [12788103.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):341-51 [12860968.001]
  • [Cites] J Virol. 2003 Aug;77(16):8957-61 [12885912.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5604-11 [14645250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 17460759.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NIGMS NIH HHS / GM / GM57411; United States / NIGMS NIH HHS / GM / R01 GM057411; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA112537; United States / NHLBI NIH HHS / HL / HL075602; United States / NCI NIH HHS / CA / CA122025; United States / NCI NIH HHS / CA / CA112537
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 3.1.6.- / Sulfatases
  • [Other-IDs] NLM/ PMC1849966
  • [General-notes] NLM/ Original DateCompleted: 20070803
  •  go-up   go-down


53. Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D, Crawford JM, Atkinson MA: Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta cells, without alterations in fractional insulin area. Diabetologia; 2009 Feb;52(2):262-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta cells, without alterations in fractional insulin area.
  • We therefore tested the hypothesis that beta cell replication is observed in non-autoimmune human pancreatic disorders in which localised inflammation or elevated gastrin levels are present.
  • METHODS: Resected operative pancreatic specimens were obtained from patients diagnosed with primary adenocarcinoma (with or without chronic severe pancreatitis) or gastrinoma.
  • Additional pancreatic tissue was obtained from autopsy control patients.
  • Patients with pancreatic adenocarcinoma and localised chronic severe pancreatitis displayed significant increases in the number of single beta cells, as well as increased beta cell replication rate and levels of neurogenic differentiation 1 in islets.
  • CONCLUSIONS/INTERPRETATION: These findings indicate that chronic severe pancreatic inflammation can be associated with significant effects on beta cell number or replication rate, depending on the distribution of the cells.
  • [MeSH-major] Adenocarcinoma / pathology. Insulin / analysis. Insulin-Secreting Cells / pathology. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):69-81 [11135322.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2553-61 [17786244.001]
  • [Cites] Annu Rev Med. 2006;57:265-81 [16409149.001]
  • [Cites] Curr Diabetes Rev. 2006 Feb;2(1):3-9 [18220612.001]
  • [Cites] Diabetologia. 2008 Jan;51(1):91-100 [17994216.001]
  • [Cites] Diabetes. 2007 Sep;56(9):2400-4 [17563060.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S95-9 [11762360.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(5-6):715-20 [16607698.001]
  • [Cites] Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):363-74 [12951644.001]
  • [Cites] Am J Surg. 2007 Oct;194(4 Suppl):S71-5 [17903450.001]
  • [Cites] Diabetologia. 2006 Aug;49(8):1838-44 [16802132.001]
  • [Cites] Pancreas. 2004 Oct;29(3):e85-9 [15367898.001]
  • [Cites] Transplantation. 2005 May 15;79(9):1091-6 [15880049.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 May;2(5):240-1 [16932290.001]
  • [Cites] Diabetes. 2007 May;56(5):1316-23 [17360983.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1855-61 [16478822.001]
  • [Cites] Pharmacol Toxicol. 2002 Dec;91(6):414-20 [12688387.001]
  • [Cites] Mol Endocrinol. 2004 Nov;18(11):2765-76 [15297605.001]
  • [Cites] Diabetes. 1971 Jun;20(6):387-96 [4104174.001]
  • [Cites] Diabetes Metab Res Rev. 2007 Feb;23(2):87-99 [17048266.001]
  • [Cites] Diabetes. 2007 Mar;56(3):634-40 [17327430.001]
  • [Cites] Curr Top Med Chem. 2007;7(12):1154-65 [17584137.001]
  • [Cites] Diabetes. 2008 Jun;57(6):1584-94 [18334605.001]
  • [Cites] Diabetes. 2005 Sep;54(9):2596-601 [16123347.001]
  • [Cites] Diabetes. 2000 Aug;49(8):1325-33 [10923633.001]
  • [Cites] Diabetes. 2007 Jul;56(7):1810-6 [17456852.001]
  • [Cites] Diabetologia. 2006 Nov;49(11):2689-96 [17016695.001]
  • [Cites] Diabetologia. 2005 Nov;48(11):2221-8 [16205882.001]
  • [Cites] Nat Biotechnol. 2005 Jul;23(7):857-61 [16003374.001]
  • [Cites] Diabetes. 2003 Jan;52(1):102-10 [12502499.001]
  • [Cites] Pflugers Arch. 2005 Jan;449(4):344-55 [15480747.001]
  • [Cites] J Intern Med. 2007 Aug;262(2):142-4 [17645582.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8078-83 [12048252.001]
  • [Cites] Diabetologia. 2005 Jan;48(1):49-57 [15616797.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2713-22 [17003335.001]
  • [Cites] Horm Metab Res. 1997 Jun;29(6):308-10 [9230353.001]
  • [Cites] Physiol Rev. 2005 Oct;85(4):1255-70 [16183912.001]
  • [Cites] Diabetes. 2008 Jan;57(1):142-9 [17959931.001]
  • [Cites] Diabetologia. 2005 Nov;48(11):2200-2 [16193285.001]
  • (PMID = 19002428.001).
  • [ISSN] 1432-0428
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Grant] United States / PHS HHS / / P01 42288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Insulin; 0 / Ki-67 Antigen
  •  go-up   go-down


54. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM: Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest; 2005 Aug;85(8):1003-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells.
  • Pancreatic adenocarcinomas display foci of duct-like structures that are positive for markers of pancreatic ductal cells.
  • To create an in vitro system to study pancreatic adenocarcinomas, we had used an hTERT cDNA to immortalize primary cells of the human pancreas.
  • In this report, we show that the immortalized cells, termed hTERT-HPNE cells, have the ability to differentiate to pancreatic ductal cells.
  • Exposing hTERT-HPNE cells to sodium butyrate and 5-aza-2'-deoxycytidine lead to the formation of pancreatic ductal cells marked by the expression of MDR-1, carbonic anhydrase II, and the cytokeratins 7, 8, and 19. hTERT-HPNE cells were found to have properties of the intermediary cells formed during acinar-to-ductal metaplasia, which included their undifferentiated phenotype, expression of Nestin, evidence of active Notch signaling, and ability to differentiate to pancreatic ductal cells.
  • These results provide further evidence for the presence in the adult pancreas of a precursor of ductal cells. hTERT-HPNE cells should provide a useful model to study acinar-to-ductal metaplasia and the role played by this process in pancreatic cancer development.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Differentiation / physiology. Pancreas / cytology. Pancreatic Neoplasms / pathology. Receptors, Cell Surface / physiology. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924149.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / NOTCH2 protein, human; 0 / Receptor, Notch2; 0 / Receptors, Cell Surface
  •  go-up   go-down


55. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR: Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage; 2009 Dec;38(6):894-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.
  • This study explores the role of 13 potentially functional polymorphisms in cytokine genes, including IL-1beta, IL-6, IL-8, IL-10, IL-18, tumor necrosis factor-alpha, and nuclear factor kappa-B subunit 1, in pain severity in patients with pancreatic cancer.
  • We evaluated a series of patients with histologically confirmed adenocarcinoma of the pancreas (n=484), who had completed a self-administered survey of pain before initiating any cancer treatment.
  • We provide preliminary evidence of the role of IL-8 in the severity of pain in pancreatic cancer patients.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2727-36 [15526319.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):777-85 [18672213.001]
  • [Cites] J Intern Med. 2005 Feb;257(2):139-55 [15656873.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 3;387(1):111-8 [10633169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Behav Brain Res. 2006 Feb 28;167(2):355-64 [16256210.001]
  • [Cites] Head Neck. 2006 Apr;28(4):313-20 [16200627.001]
  • [Cites] Neurosci Lett. 2006 Aug 14;404(1-2):154-8 [16777324.001]
  • [Cites] Pain. 2006 Dec 15;126(1-3):294-308 [16949747.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):135-50 [11195407.001]
  • [Cites] J Neurosci. 2001 Jul 15;21(14):5027-35 [11438578.001]
  • [Cites] Eur Spine J. 2002 Feb;11(1):62-6 [11931066.001]
  • [Cites] Adv Exp Med Biol. 2003;521:1-21 [12617561.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):50-3 [14681913.001]
  • [Cites] Am J Med. 2004 Mar 1;116(5):318-24 [14984817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Qual Life Res. 2004 Oct;13(8):1369-79 [15503832.001]
  • [Cites] Brain Res. 1994 Aug 15;654(1):15-26 [7982088.001]
  • [Cites] Life Sci. 1995;57(11):1011-26 [7658909.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Pain. 1995 Dec;63(3):289-302 [8719529.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7710-3 [10393885.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2745-51 [18086782.001]
  • (PMID = 19692203.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128069; United States / NCI NIH HHS / CA / R03 CA128069-01A2; United States / NCI NIH HHS / CA / CA128069-01A2; United States / NCI NIH HHS / CA / K07 CA109043-05; United States / NCI NIH HHS / CA / CA109043-05; United States / NCI NIH HHS / CA / K07 CA109043; United States / NCI NIH HHS / CA / CA128069; United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / CA101936; United States / NCI NIH HHS / CA / CA109043
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS131146; NLM/ PMC2795073
  •  go-up   go-down


56. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg; 2005 Mar;189(3):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas.
  • However, the relationship between platelet count and prognosis in pancreatic cancer remains unresolved.
  • METHODS: A chart review of patients undergoing resection for pancreatic adenocarcinoma was undertaken.
  • RESULTS: Between June 1995 and March 2003, 109 patients (63% male) with a median age of 68 years (range 42 to 85 years) underwent resection for pancreatic cancer.
  • CONCLUSIONS: Increased preoperative platelet count is associated with adverse survival outcome in patients undergoing resection for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / mortality. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / mortality. Platelet Count

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792750.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Vosters O, Beuneu C, Goldman M, Verhasselt V: N-acetylcysteine derivative inhibits CD40-dependent proinflammatory properties of human pancreatic duct cells. Pancreas; 2008 May;36(4):363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-acetylcysteine derivative inhibits CD40-dependent proinflammatory properties of human pancreatic duct cells.
  • METHODS: We assessed the effects of Nacystelyn on CD40 expression and function in human caucasian pancreatic adenocarcinoma, ATCC n degrees THB-80 (CAPAN-2) cells, a human pancreatic duct cell line.
  • CONCLUSIONS: Our data suggest that Nacystelyn could be considered as a useful tool to prevent immune and inflammatory responses in pancreatic disorders by interfering with the CD40 pathway in pancreatic duct cells.
  • [MeSH-major] Acetylcysteine / analogs & derivatives. Acetylcysteine / pharmacology. Antigens, CD40 / antagonists & inhibitors. Antigens, CD40 / genetics. Inflammation / prevention & control. Lysine / analogs & derivatives. Pancreatic Ducts / physiopathology
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Line, Tumor. Gene Expression Regulation, Neoplastic / drug effects. Humans. NF-kappa B / drug effects. NF-kappa B / genetics. Pancreatic Neoplasms / pathology. Transcription, Genetic / drug effects

  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437082.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / N-acetylcysteine lysinate; 0 / NF-kappa B; K3Z4F929H6 / Lysine; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


58. Sanchez SE, Trevino JG: Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem; 2008;15(17):1674-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current adjuvant and targeted therapies for pancreatic adenocarcinoma.
  • Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year.
  • Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer.
  • In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Pharmaceutic / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673217.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic
  • [Number-of-references] 76
  •  go-up   go-down


59. Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH: Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg; 2010;2010:579672
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy.
  • BACKGROUND: For M1 pancreatic adenocarcinomas pancreatic resection is usually not indicated.
  • However, in highly selected patients synchronous metastasectomy may be appropriate together with pancreatic resection when operative morbidity is low.
  • MATERIALS AND METHODS: From January 1, 2004 to December, 2007 a total of 20 patients with pancreatic malignancies were retrospectively evaluated who underwent pancreatic surgery with synchronous resection of hepatic, adjacent organ, or peritoneal metastases for proven UICC stage IV periampullary cancer of the pancreas.
  • The primary tumor was located in the pancreatic head (n = 9, 45%), in pancreatic tail (n = 9, 45%), and in the papilla Vateri (n = 2, 10%).
  • Median postoperative survival was 10.7 months (2.6-37.7 months) which was not significantly different from a matched-pair group of patients who underwent pancreatic resection for UICC adenocarcinoma of the pancreas (median survival 15.6 months; P = .1).
  • CONCLUSION: Pancreatic resection for M1 periampullary cancer of the pancreas can be performed safely in well-selected patients.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Pancreatectomy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Oncologist. 2008 May;13(5):562-76 [18515741.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):118-27 [17066229.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):265-73 [17318801.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2212-7 [17538165.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):46-51 [17592290.001]
  • [Cites] Z Gastroenterol. 2007 Jun;45(6):487-523 [17607616.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):246-53 [17667503.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S81-6 [17916525.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2484-92 [17941009.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):86-90 [17710505.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):300-9 [18216537.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • (PMID = 21197481.001).
  • [ISSN] 1607-8462
  • [Journal-full-title] HPB surgery : a world journal of hepatic, pancreatic and biliary surgery
  • [ISO-abbreviation] HPB Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3010622
  •  go-up   go-down


60. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol; 2005 Sep;18(9):1193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DeltaNp63 expression in pancreas and pancreatic neoplasia.
  • It is not known whether this marker may have any application in another exocrine organ, the pancreas.
  • A total of 25 cases were non-neoplastic pancreata, 25 were pancreatic intraepithelial neoplasia (PanIN) of various grades, and 50 were examples of pancreatic ductal adenocarcinoma.
  • No DNp63 expression was noted in normal pancreatic ducts.
  • DNp63 labeling was also noted in those incidental microcysts lined by attenuated cells, seen amidst normal pancreatic lobules.
  • In conclusion, (I) DNp63 is a reliable marker of squamous differentiation in the pancreas.
  • Among invasive carcinomas, it seems to be entirely specific for areas of squamous differentiation. (II) Those incidental microcysts seen in acinar lobules and lined by attenuated cells are also positive for DNp63, which suggests that they may be metaplastic in nature, and that they do not represent neoplastic cells. (III) Unlike the ducts of other exocrine organs, breast and prostate, there are no DNp63-expressing cells in the normal pancreatic ducts, and therefore, this marker cannot be used in distinguishing invasive carcinomas from the non-invasive ducts. (IV) No p63-expressing 'stem' cells are present in the pancreas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Phosphoproteins / biosynthesis. Trans-Activators / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976814.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / PAR-02-068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


61. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • AIMS: Intraductal tubular adenoma (ITA) is an uncommon intraluminal polypoid lesion that occurs in the main pancreatic duct and involves the main pancreatic duct in the region of head or body.
  • Pancreatic intraepithelial neoplasia (PanIN) 1A and B was present in smaller ducts of all cases.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. LeBlanc JK, Emerson RE, Dewitt J, Symms M, Cramer HM, McHenry L, Wade CL, Wang X, Musto P, Eichelberger L, Al-Haddad M, Johnson C, Sherman S: A prospective study comparing rapid assessment of smears and ThinPrep for endoscopic ultrasound-guided fine-needle aspirates. Endoscopy; 2010 May;42(5):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the study was to compare sensitivity and accuracy of ThinPrep versus the smear method in pancreas and lymph node samples obtained by EUS-FNA.
  • PATIENTS AND METHODS: Patients with suspected malignancy in the pancreas or lymph node underwent EUS-FNA.
  • RESULTS: A total of 130 patients (36 % women, mean age 63 years) underwent EUS-FNA of 139 sites (50 pancreas, 89 lymph node).
  • Malignancy was confirmed in 47 pancreas samples (94 %) and 48 lymph node samples (54 %).
  • For pancreatic cancer, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the ThinPrep versus the smear method were: 62 % versus 98 %, 100 % versus 100 %, 100 % versus 100 %, 14 % versus 75 %, and 64 % versus 98 %, respectively.
  • CONCLUSIONS: The smear method is more sensitive and accurate than ThinPrep in detecting malignancy from EUS-FNA samples of the pancreas and lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Biopsy, Fine-Needle / methods. Endosonography / methods. Histocytological Preparation Techniques / methods. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Pancreatectomy. Prospective Studies. Reproducibility of Results. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20101566.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Wiseman JM, Puolitaival SM, Takáts Z, Cooks RG, Caprioli RM: Mass spectrometric profiling of intact biological tissue by using desorption electrospray ionization. Angew Chem Int Ed Engl; 2005 Nov 4;44(43):7094-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / chemistry. Lipids / chemistry. Liver Neoplasms / chemistry. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adipose Tissue / chemistry. Animals. Brain. Humans. Liver / chemistry. Liver / pathology. Mice. Pancreas / chemistry. Rats

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259018.001).
  • [ISSN] 1433-7851
  • [Journal-full-title] Angewandte Chemie (International ed. in English)
  • [ISO-abbreviation] Angew. Chem. Int. Ed. Engl.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5R01 GM58008-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


64. Hruban RH, Wilentz RE, Maitra A: Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med; 2005;103:1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and analysis of precursors to invasive pancreatic cancer.
  • Histologically distinct noninvasive precursor lesions have been recognized in the pancreas for close to a century.
  • The "pancreatic intraepithelial neoplasia" or PanIN system was developed at a National Cancer Institutes sponsored think tank in Park City, Utah.
  • Numerous studies have now demonstrated that genetic alterations in cancer-associated genes are more common in higher grade PanIN lesions then they are in lower grade PanIN lesions, and that higher grade PanIN lesions have many of the same genetic alterations that are found in invasive ductal adenocarcinomas of the pancreas.
  • Thus, just as there is a progression in the colorectal of adenomas to invasive adenocarcinoma, so too is there a progression in the pancreas of histologically low-grade PanIN, to high-grade PanIN to invasive ductal adenocarcinoma.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542896.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


65. Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM: Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol; 2007 Jun;60(6):622-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using immunohistochemical analysis, the expression of galectin 4 and meprin alpha was investigated in 10 MOCs and in 38 mucinous adenocarcinomas of colon, pancreas, stomach and appendix, the most common sites of origin of ovarian metastases.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / metabolism. Gastrointestinal Neoplasms / pathology. Metalloendopeptidases / metabolism. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Diagnosis, Differential. Female. Galectin 4 / metabolism. Humans. Immunoenzyme Techniques. Keratin-20 / metabolism. Keratin-7 / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):52-7 [14668551.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Glycoconj J. 2004;20(4):247-55 [15115909.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):641-3 [15166272.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):876-8 [7490328.001]
  • [Cites] Eur J Biochem. 1997 Aug 15;248(1):225-30 [9310382.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1127-33 [10070973.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):55-60 [15722794.001]
  • [Cites] J Pathol. 2005 Apr;205(5):615-22 [15732140.001]
  • [Cites] Pathol Int. 2005 May;55(5):231-43 [15871720.001]
  • [Cites] FEBS Lett. 2005 Jun 13;579(15):3317-22 [15943977.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):331-9 [16170669.001]
  • [Cites] Hum Pathol. 2005 Nov;36(11):1217-25 [16260276.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):40650-8 [12189145.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1849-58 [12673710.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • (PMID = 16822880.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 4; 0 / Keratin-20; 0 / Keratin-7; 0 / Neoplasm Proteins; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.18 / meprin A
  • [Other-IDs] NLM/ PMC1955076
  •  go-up   go-down


66. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg; 2007 Oct;205(4):558-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
  • BACKGROUND: The American Joint Committee on Cancer (AJCC) 6(th) edition staging system for pancreatic adenocarcinoma specifically excludes pancreatic neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist.
  • Our objective was to evaluate the feasibility of applying the AJCC pancreatic adenocarcinoma staging system to PNETs.
  • When comparing outcomes to those of patients with pancreatic adenocarcinoma, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001).
  • CONCLUSIONS: When applied to PNETs, the AJCC staging system for pancreatic adenocarcinoma provides survival discrimination by stage for surgical and nonsurgical patients.
  • Survival rates are better for PNETs than for pancreatic adenocarcinoma, but the staging system can effectively stratify patients with PNETs.
  • [MeSH-major] Neoplasm Staging. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903729.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ: Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford); 2009 Nov;11(7):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
  • BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495714.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2785957
  •  go-up   go-down


68. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O: Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med; 2010 Dec;31(6):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses.
  • PURPOSE: Contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) for the assessment of microcirculation and the delineation of pancreatic tumors in order to characterize and stage them has only recently become available for commercial use, and few reports have been published.
  • The purpose of the study was the qualitative and quantitative digital image analysis of pancreatic adenocarcinomas using conventional endoscopic ultrasonography (EUS) and CEH-EUS and the evaluation of whether contrast medium injection modified adenocarcinoma staging and patient management.
  • MATERIALS AND METHODS: In each of 30 prospectively examined patients with suspected pancreatic solid lesions, CEH-EUS was performed using the same quantity of the contrast agent SonoVue and a low mechanical index (0.3 - 0.4), followed by EUS-FNA.
  • The histology, based on EUS-FNA or surgery and 9 months of follow-up, was: pancreatic adenocarcinoma (n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
  • RESULTS: CEH-EUS showed a hypoenhanced pattern in 14 cases of adenocarcinoma and in 10 cases of chronic pancreatitis.
  • The index of the contrast uptake ratio was significantly lower in adenocarcinoma than in mass-forming chronic pancreatitis.
  • A cut-off uptake ratio index value of 0.17 for diagnosing adenocarcinoma corresponded to an AUC (CI 95%) of 0.86 (0.67 - 1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%.
  • The size of the pancreatic mass was assessed significantly more effectively by CEH-EUS but adenocarcinoma staging was not modified.
  • CONCLUSION: The majority of cases of both pancreatic adenocarcinoma and chronic pancreatitis were hypoenhanced and visual discrimination was not possible.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Pancreatic Neoplasms / ultrasonography. Tumor Burden / physiology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21080306.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


69. O'Connell AM, Lyon SM, O'Sullivan P, Given MF, Morrin M, Lee MJ: Secretin-assisted CT of the pancreas: improved pancreatic enhancement and tumour conspicuity. Clin Radiol; 2008 Apr;63(4):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretin-assisted CT of the pancreas: improved pancreatic enhancement and tumour conspicuity.
  • PURPOSE: The primary aim of this prospective pilot study was to determine if the administration of intravenous secretin prior to contrast-enhanced computed tomography (CT) improves pancreatic enhancement and pancreatic tumor conspicuity.
  • 35 patients (18 men, 17 women; mean age, 67.6 years; age range; 25 to 86 years) with known or suspected pancreatic malignancy or an abdominal malignancy underwent a helical CT of the pancreas.
  • The pancreas was first localised on an unenhanced scan using 10mm sections.
  • Following 120 ml of intravenous 300 mg/ml of non ionic contrast medium (CM), injected at a rate of 5 ml/s, images of the pancreas (3mm slice thickness) and liver (8mm slice thickness) were obtained at 40 and 70 seconds respectively.
  • The attenuation in Hounsfield Units (HU) was recorded on non-contrast, pancreatic phase and portal venous phases for both secretin and non-secretin CTs, in the pancreas and pancreatic tumors (where present).
  • Tumor conspicuity was calculated (in the 19 patients with pancreatic adenocarcinomas) by subtracting pancreatic tumor attenuation from pancreatic attenuation.
  • RESULTS: A significant increase in pancreatic enhancement was observed when secretin was injected at 2 to 3 min before contrast material injection (the increase in pancreatic density following secretin at 2 min was 31.5+/-10 HU (29.2%) (p=.035); and at 3 min was 23.2+/-7.8 HU (22.7%) (p=.041).
  • Pancreatic tumor conspicuity in the pancreatic phase was most marked when secretin was injected between 2 to 4 min before contrast medium, with 4 min showing a statistically significant increase in tumor conspicuity, 48.2+/-14.2 HU (p=.04).
  • CONCLUSION: Imaging in the pancreatic phase 2 to 4 min after administration of intravenous secretin leads to greater enhancement of the pancreas with greater tumor conspicuity, than imaging without secretin.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenocarcinoma / radiography. Hormones / administration & dosage. Pancreatic Neoplasms / radiography. Secretin / administration & dosage. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325360.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Hormones; 1393-25-5 / Secretin
  •  go-up   go-down


70. Belsley NA, Pitman MB, Lauwers GY, Brugge WR, Deshpande V: Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer; 2008 Apr 25;114(2):102-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystadenoma of the pancreas: limitations and pitfalls of endoscopic ultrasound-guided fine-needle aspiration biopsy.
  • BACKGROUND: Expectant management of serous cystadenoma (SCA) of the pancreas requires an accurate preoperative diagnosis.
  • Group III was comprised of 2 nonserous and potentially malignant cysts of the pancreas for which a preoperative diagnosis of SCA was considered.
  • The authors also evaluated the presence of hemosiderin-laden macrophages in a series of 110 FNA specimens from histologically confirmed neoplastic mucinous cysts of the pancreas and 45 pseudocysts of the pancreas.
  • A cytologic diagnosis of SCA was made prospectively in only 1 CT-guided case.
  • A preoperative diagnosis of SCA remains a challenge, and an EUS-guided FNAB is unlikely to provide the high level of diagnostic accuracy necessary to permit a nonoperative approach.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biopsy, Fine-Needle. Cystadenoma, Serous / pathology. Endoscopy / methods. Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cyst Fluid / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) American Cancer Society.
  • (PMID = 18260088.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC: Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma. Am J Clin Pathol; 2005 Nov;124(5):697-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.
  • Our objectives were to devise a cytologic grading system and determine whether it would predict survival of patients with solid-type pancreatic adenocarcinoma.
  • We devised a grading system that independently predicted survival in patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203289.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azure Stains; 0 / Romanowsky-Giemsa stain; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


72. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, Monsurrò V, Barbi S, Scarpa A, Nisticò P, Giovarelli M, Novelli F: An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer; 2009 Aug 1;125(3):639-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
  • Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a very poor 5-year survival rate. alpha-Enolase is a glycolytic enzyme that also acts as a surface plasminogen receptor.
  • It is thus a promising and clinically relevant molecular target candidate for immunotherapeutic approaches as new adjuvants to conventional treatments in pancreatic cancer.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / immunology. Cell Proliferation. Pancreatic Neoplasms / enzymology. Pancreatic Neoplasms / immunology. Phosphopyruvate Hydratase / metabolism. T-Lymphocytes
  • [MeSH-minor] Animals. Antibody Formation. Blotting, Western. Cell Line, Tumor. Dendritic Cells / immunology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunity, Cellular. Immunoglobulin G / blood. Immunohistochemistry. Interferon-gamma / secretion. Keratinocytes / immunology. Mice. Pancreas / enzymology. Pancreas / immunology. Skin / cytology. T-Lymphocytes, Cytotoxic / immunology. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • University of Turin Instituional Repository AperTO. Full Text from .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425054.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


73. Kang CM, Lee JW: Spleen preserving laparoscopic distal pancreatectomy with segmental resection of splenic artery in a solid pseudo papillary tumor of the pancreas. Hepatogastroenterology; 2009 Jul-Aug;56(93):1207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen preserving laparoscopic distal pancreatectomy with segmental resection of splenic artery in a solid pseudo papillary tumor of the pancreas.
  • Laparoscopic distal pancreatectomy is suitable for benign and premalignant neoplasms located in the body and tail of the pancreas.
  • We present a case of 32-year-old female patient with a solid pseudopapillary tumor of the pancreas treated by spleen-preserving laparoscopic distal pancreatectomy with segmental resection of the splenic artery and splenic vein intact.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Splenic Artery / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760971.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


74. Gbelcová H, Lenícek M, Zelenka J, Knejzlík Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T, Vítek L: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer; 2008 Mar 15;122(6):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in antitumor effects of various statins on human pancreatic cancer.
  • The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer.
  • The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines.
  • In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins.
  • These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18027870.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


75. Gourgiotis S, Salemis NS, Kanakopoulos D, Germanos S: Pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: could pancreaticogastrostomy be the anastomosis of choice? JOP; 2010;11(4):407-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: could pancreaticogastrostomy be the anastomosis of choice?
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Gastrostomy / methods. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601823.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Evaluation Studies; Letter
  • [Publication-country] Italy
  •  go-up   go-down


76. Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S: Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol; 2007 Mar;35(3):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
  • Mesothelin is a potential marker of pancreatic adenocarcinoma that was recently identified by serial analysis of gene expression.
  • We evaluated the sensitivity and specificity of mesothelin as a marker of pancreatic adenocarcinoma on destained Papanicolaou (Pap) smears and unstained cellblocks from 28 patients using a monoclonal antibody to mesothelin.
  • Focal positivity for mesothelin was noted in benign pancreatic tissue in one of 10 cases.
  • The overall sensitivity and specificity of mesothelin as a marker for pancreatic adenocarcinoma were 68% and 90%, respectively.
  • The presence of occasional mesothelin expression in benign tissue, its very focal expression in malignant tissue may limit the utility of mesothelin as a marker of pancreatic adenocarcinomas in fine-needle aspiration (FNA) specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Membrane Glycoproteins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Pancreas / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304533.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


77. Ikeda M, Ryu M, Yamazaki K, Tsuchiya M, Kaneko H, Miyairi M: Long-term follow-up of a pouching operation after pancreaticoduodenectomy using a double-jejunal pouch. Hepatogastroenterology; 2007 Dec;54(80):2398-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year old male was referred with intraductal papillary adenocarcinoma of the pancreas.
  • A modification of the Imanaga reconstructive method using a double-jejunal pouch was performed for the pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265674.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


78. Kleeff J, Michalski C, Friess H, Büchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas; 2006 Aug;33(2):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: from bench to 5-year survival.
  • Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with an overall 5-year survival rate of less than 4%.
  • Technically, pancreatic surgery has advanced, with acceptable morbidity and mortality rates in high-volume centers.
  • Translational research combined with clinical trials will hopefully lead to improved survival and better quality of life for pancreatic cancer patients in the future.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Neoplasm Recurrence, Local / mortality. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868475.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 99
  •  go-up   go-down


79. Zhang B, Zhao WH, Zhou WY, Yu WS, Yu JM, Li S: Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect Prev; 2007;31(6):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma.
  • BACKGROUND: We analyzed the intratumoral and peritumoral microvessel density (MVD) and microlymphatic vessel density (MLVD) in pancreatic adenocarcinoma (PAC) and recorded the expression of vascular endothelial growth factor (VEGF)-C and -D.
  • [MeSH-major] Adenocarcinoma / physiopathology. Lymphangiogenesis / physiology. Neovascularization, Pathologic / physiopathology. Pancreatic Neoplasms / physiopathology. Vascular Endothelial Growth Factor C / biosynthesis. Vascular Endothelial Growth Factor D / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061373.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


80. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C: Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw; 2007 Nov;5(10):998-1033
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
  • [MeSH-major] Adenocarcinoma. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053426.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 196
  •  go-up   go-down


81. Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, Buchler MW, Z'graggen K: Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett; 2007 Jul 18;252(2):290-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential target antigens for immunotherapy in human pancreatic cancer.
  • Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms.
  • METHODS: Pancreatic adenocarcinoma tumor samples (n=130) were obtained intraoperatively, control tissues (n=23) were collected from cadaveric donor and from patients with chronic pancreatitis.
  • Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues.
  • RESULTS: Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples.
  • No expression of CT antigens was found in non-malignant pancreatic tissue with the exception of SSX-4 and and SSX-2.
  • The concomitant expression of SSX-4 in both malignant and non-malignant pancreatic tissue is a new finding which may raise concerns for immunotherapy.
  • However, HERV-K-MEL is expressed with a relatively high prevalence and may be a candidate for specific immunotherapy in a large subgroup of pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / therapy. Antigens, Neoplasm / immunology. Immunotherapy. Pancreatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320278.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA Primers; M801H13NRU / Azacitidine
  •  go-up   go-down


82. Förster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM: Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med; 2006 Jan;47(1):140-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A human pancreatic adenocarcinoma xenograft model (HPAC) in nude mice was used.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / radiotherapy. Biotin / analogs & derivatives. Drug Delivery Systems / methods. Gallium Radioisotopes / pharmacokinetics. Kidney / metabolism. Organometallic Compounds / pharmacokinetics. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BIOTIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391198.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R2CA83084; United States / NCRR NIH HHS / RR / S10-RR017935
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DOTA-biotin; 0 / Gallium Radioisotopes; 0 / Immunoglobulin Fragments; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 6SO6U10H04 / Biotin; 9013-20-1 / Streptavidin
  •  go-up   go-down


83. Lotem J, Netanely D, Domany E, Sachs L: Human cancers overexpress genes that are specific to a variety of normal human tissues. Proc Natl Acad Sci U S A; 2005 Dec 20;102(51):18556-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 91 stable clusters obtained, 24 clusters included genes preferentially expressed either only in hematopoietic tissues or in hematopoietic and one to two other tissues; 28 clusters included genes preferentially expressed in various nonhematopoietic tissues such as neuronal, testis, liver, kidney, muscle, lung, pancreas, and placenta.
  • [MeSH-minor] Adenocarcinoma / genetics. Cell Line. Cell Line, Tumor. Health. Humans. Leukemia / classification. Leukemia / genetics. Multigene Family / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12079-84 [11035779.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3555-64 [9317155.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3156-65 [11420732.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):339-46 [12191633.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1035-42 [12481426.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1585-92 [12490442.001]
  • [Cites] Blood. 2003 Jan 15;101(2):383-9 [12393558.001]
  • [Cites] Leukemia. 2003 Jan;17(1):9-16 [12529654.001]
  • [Cites] Adv Cancer Res. 2003;88:31-52 [12665052.001]
  • [Cites] Front Biosci. 2003 May 1;8:s206-22 [12700034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Lancet. 2003 Jul 19;362(9379):205-9 [12885482.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16022-7 [15505217.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2390-7 [15832406.001]
  • [Cites] Blood. 2005 May 1;105(9):3488-92 [15650059.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4881-7 [15930309.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Oct;25(10):760-8 [14528097.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):211-4 [15069314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Semin Hematol. 1981 Jan;18(1):72-7 [7010612.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:271-2 [9209362.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3139-55 [11420731.001]
  • (PMID = 16339305.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1317977
  •  go-up   go-down


84. Sawey ET, Johnson JA, Crawford HC: Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A; 2007 Dec 4;104(49):19327-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway.
  • Acinar-to-ductal metaplasia in the pancreas is associated with an increased risk for tumorigenesis.
  • Besides being necessary for acinar transdifferentiation, it was found that MMP-7 activity was sufficient to induce the process, indicating that molecular signals capable of initiating MMP-7 expression also have the potential to induce formation of metaplastic epithelia in the pancreas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1416-26 [10579983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1825-35 [10669757.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):12-20 [10962434.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1355-8 [11396212.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(21):2615-24 [12354787.001]
  • [Cites] Cell. 2002 Nov 27;111(5):635-46 [12464176.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1235-40 [14977820.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1285-90 [2982487.001]
  • [Cites] Eur J Cell Biol. 1990 Feb;51(1):64-75 [2184038.001]
  • [Cites] Mol Carcinog. 1991;4(6):527-33 [1793490.001]
  • [Cites] Princess Takamatsu Symp. 1994;24:152-61 [8983072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Cell. 1997 Jul 25;90(2):271-80 [9244301.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • [Cites] FEBS Lett. 1998 Sep 11;435(1):39-44 [9755855.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1254-62 [9797382.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5500-6 [9850086.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):117-30 [16354684.001]
  • [Cites] Biochem J. 2006 Feb 1;393(Pt 3):679-85 [16201968.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] J Cell Biol. 2007 Feb 12;176(4):445-58 [17296795.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • (PMID = 18042722.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01CA100126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Notch; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ PMC2148289
  •  go-up   go-down


85. Manzanet G, Suelves C, Trías A, Calderón R, Morón R, Corell R, Navarro J, Clarós A, Peiró E, Todolí G, Castell L: [Cephalic pancreaticoduodenectomy with mesentericoportal venous reconstruction. Technical features]. Cir Esp; 2006 Aug;80(2):105-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cephalic pancreaticoduodenectomy (CPD) with mesentericoportal venous resection increases the resectability rate of pancreatic tumors.
  • We present a case of adenocarcinoma of the pancreatic head infiltrating the superior mesenteric-portal vein confluence that underwent surgery in our hospital.
  • [MeSH-major] Adenocarcinoma / surgery. Mesenteric Veins / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Portal Vein / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945309.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M: Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res; 2005 Apr 15;11(8):2840-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility.
  • PURPOSE: Patients with pancreatic adenocarcinoma have a poor prognosis due to the extraordinary high invasive capacity of this tumor.
  • We recently reported that after protein kinase C activation, colocalization of alpha6beta4 with the tetraspanin CO-029 strongly supports migration of a rat pancreatic adenocarcinoma.
  • The finding led us to explore whether and which integrin-tetraspanin complexes influence the motility of human pancreatic tumors.
  • EXPERIMENTAL DESIGN: Integrin and tetraspanin expression of pancreatic and colorectal adenocarcinoma was evaluated with emphasis on colocalization and the impact of integrin-tetraspanin associations on tumor cell motility.
  • RESULTS: The majority of pancreatic and colorectal tumors expressed the alpha2, alpha3, alpha6, beta1, and beta4 integrins and the tetraspanins CD9, CD63, CD81, CD151, and CO-029.
  • CD63, CD81, and beta1 expression was observed at comparably high levels in healthy pancreatic tissue. alpha3beta1 frequently colocalized and coimmunoprecipitated with CD9, CD81, and CD151, whereas alpha6beta4 colocalized and coimmunoprecipitated mostly with CD151 and CO-029.
  • CONCLUSION: alpha6beta4 is selectively up-regulated in pancreatic and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Membrane Proteins / analysis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837731.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD151; 0 / Antigens, Neoplasm; 0 / CD151 protein, human; 0 / Cd151 protein, rat; 0 / Integrins; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / TSPAN8 protein, human; 0 / Tetraspanins
  •  go-up   go-down


87. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, Pisters PW: Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg; 2005 Jun;140(6):584-9; discussion 589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer.
  • HYPOTHESIS: The required sample size of a prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy plus extended lymphadenectomy for pancreatic adenocarcinoma is prohibitively large, making such a trial infeasible.
  • PATIENTS: We identified 158 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma with separate pathologic analysis of second-echelon lymph nodes, defined as lymph nodes along the proximal hepatic artery and/or the great vessels.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pancreatic Neoplasms / surgery. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967906.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M: A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol; 2010 Dec 01;3(6):373-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
  • BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer.
  • We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic cancer patients.
  • METHODS: Patients with resected pancreatic adenocarcinoma received erlotinib and capecitabine concurrently with IMRT delivered at 1.8 Gy daily in 28 fractions (total = 50.4 Gy).
  • CONCLUSIONS: When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m(2) twice daily (Monday to Friday) can be administered safely in resected pancreas cancer patients, and is the recommended regimen for efficacy studies using this regimen.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151476.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104900
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3000462
  •  go-up   go-down


89. Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D, Nall C, Lu M, Ajlouni M, Movsas B, Kim JH: Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther; 2007 Sep;15(9):1600-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.
  • In preparation for a Phase I trial, we evaluated the efficacy and toxicity of replication-competent adenovirus-mediated suicide gene therapy in combination with radiation in a preclinical model of pancreatic cancer.
  • Human MiaPaCa-2 and PANC-1 pancreatic adenocarcinoma cells were found to be sensitive to the oncolytic effects of the Ad5-yCD/mutTK(SR39)rep-ADP adenovirus and also to the cytotoxic effects of the yeast cytosine deaminase (yCD) and herpes simplex virus thymidine kinase (HSV-1 TK(SR39)) genes in vitro.
  • Injection of Ad5-yCD/mutTK(SR39)rep-ADP in the dog pancreas at doses (10(12) virus particle (vp)) to be used in humans resulted in mild pancreatitis but not peritonitis or hepatotoxicity.
  • [(18)F]-FHBG uptake was readily detected in the pancreas but not in other major abdominal organs, indicating that little of the injected adenovirus disseminates to collateral tissues.
  • These results demonstrate that Ad5-yCD/mutTK(SR39)rep-ADP-mediated suicide gene therapy has the potential to augment the effectiveness of pancreatic radiotherapy without resulting in excessive toxicity.
  • Hence they provide the scientific basis for an ongoing Phase I trial in pancreatic cancer.
  • [MeSH-major] Adenoviridae / genetics. Cytosine Deaminase / genetics. Genetic Therapy / methods. Pancreatic Neoplasms / therapy. Thymidine Kinase / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551507.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA097012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase; EC 3.5.4.1 / Cytosine Deaminase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


90. Søreide K, Immervoll H, Molven A: [Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen; 2006 Mar 23;126(7):905-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Precursors to pancreatic cancer].
  • BACKGROUND: Pancreatic adenocarcinoma is a relatively frequent cancer with an extremely poor prognosis.
  • Until recently, the natural history of pancreatic adenocarcinoma has not been possible to study, but the identification of precursor lesions (pancreatic intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive adenocarcinoma.
  • MATERIAL AND METHODS: Relevant literature from the period of 1996-2005 was found by searching the Medline database, combining the terms "pancreas", "cancer", "PanIN" and "neoplasia".
  • RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to pancreatic adenocarcinoma.
  • PanIN grade I to III represent stepwise morphological alterations in the pancreatic ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal adenocarcinoma.
  • Increased knowledge about pancreatic carcinogenesis may pave the way for prevention strategies, early detection, and new treatment options, thus ultimately improving the prognosis of the patients.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554881.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


91. Hong SH, Misek DE, Wang H, Puravs E, Hinderer R, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM: Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomark Insights; 2006;1:175-183
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer.
  • Pancreatic cancer has a poor prognosis, in part due to lack of early detection.
  • The identification of circulating tumor antigens or their related autoantibodies provides a means for early cancer diagnosis.
  • We have used a proteomic approach to identify proteins that commonly induce a humoral response in pancreatic cancer.
  • Proteins from a pancreatic adenocarcinoma cell line (Panc-1) were subjected to two-dimensional PAGE, followed by Western blot analysis in which individual sera were tested for autoantibodies.
  • Sera from 36 newly diagnosed patients with pancreatic cancer, 18 patients with chronic pancreatitis and 15 healthy subjects were analyzed.
  • Autoantibodies were detected against a protein identified by mass spectrometry as vimentin, in sera from 16/36 patients with pancreatic cancer (44.4%).
  • Pancreatic tumor tissues showed greater than a 3-fold higher expression of total vimentin protein than did the lung, colon, and ovarian tumors that were analyzed.
  • The detection of autoantibodies to this specific isoform of vimentin may have utility for the early diagnosis of pancreatic cancer.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769604.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084953-059002; United States / NCI NIH HHS / CA / U01 CA084982; United States / NCI NIH HHS / CA / U19 CA084953
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


92. Nuernberg D, Ignee A, Dietrich CF: [Ultrasound in gastroenterology. Biliopancreatic system]. Med Klin (Munich); 2007 Feb 15;102(2):112-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GALLBLADDER: Ultrasound has become widely accepted for the diagnosis of gallbladder disease.
  • PANCREAS: In diagnostic imaging of the pancreas ultrasound stands at the beginning of a diagnostic cascade.
  • Ductal adenocarcinoma seems to be less vascularized in comparison to the surrounding tissue, while endocrine tumors and macro- and microcystic adenoma are rather hypervascularized.
  • [MeSH-major] Biliary Tract Diseases / ultrasonography. Pancreatic Diseases / ultrasonography
  • [MeSH-minor] Adenoma / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Carcinoma / ultrasonography. Cholangiocarcinoma / ultrasonography. Cholangitis, Sclerosing / ultrasonography. Cholecystitis / ultrasonography. Choledocholithiasis / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Gallbladder Neoplasms / ultrasonography. Humans. Middle Aged. Pancreatic Neoplasms / ultrasonography. Pancreatitis / ultrasonography. Polyps / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323018.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 228
  •  go-up   go-down


93. Oettle H, Neuhaus P: Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs; 2007;67(16):2293-310
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in pancreatic cancer: a critical appraisal.
  • Adenocarcinoma of the pancreas carries a grim prognosis.
  • More recently, the ESPAC (European Study Group for Pancreatic Cancer)-1 trial even indicated a detrimental effect of chemoradiotherapy, while chemotherapy with 5-FU was shown to have a significant positive impact on long-term survival.
  • More recently, gemcitabine, which is the most effective single agent in advanced pancreatic cancer, has also been evaluated in the adjuvant setting.
  • [MeSH-major] Adenocarcinoma. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Drugs. 2007;67(17):2487-90; discussion 2491-3 [18034586.001]
  • [CommentIn] Drugs. 2007;67(17):2481-5; discussion 2491-3 [18034585.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8 [11395232.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):235-44 [16183477.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1528-35 [9427017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Tumori. 1995 Jan-Feb;81(1):23-31 [7754537.001]
  • [Cites] Anticancer Drugs. 2000 Nov;11(10):771-86 [11142685.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):689-97 [16713541.001]
  • [Cites] Cancer. 1973 Dec;32(6):1341-5 [4127980.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):151-6 [9745081.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1483-7 [11121652.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Oncology. 2005;68(2-3):239-45 [16015040.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):205-19 [6351303.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):543-9 [14663369.001]
  • [Cites] Ann Oncol. 2001 May;12(5):681-4 [11432628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1081-7 [11072166.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5 [15218576.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):644-50 [9684110.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Oct;13(4):663-74, ix [15350940.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):332-3; author reply 333 [16858208.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Arch Surg. 2001 Mar;136(3):343-7 [11231859.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):806-13 [12454519.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):504-8 [16633830.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):53-8 [9127174.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5 [15215490.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • (PMID = 17983252.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Number-of-references] 53
  •  go-up   go-down


94. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F: Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem; 2007 Apr;53(4):629-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker.
  • BACKGROUND: Patients with pancreatic adenocarcinomas have a poor prognosis because of late clinical manifestation and the tumor's aggressive nature.
  • We used proteomic techniques to search for markers of pancreatic carcinoma.
  • METHODS: We performed protein profiling of microdissected cryostat sections of 9 pancreatic adenocarcinomas and 10 healthy pancreatic tissue samples using ProteinChip technology (surface-enhanced laser desorption/ionization).
  • We used ELISA to quantify these proteins in preoperative serum samples from 35 patients with pancreatic cancer and 37 healthy individuals.
  • We then detected HSP27 in sera of patients by use of ELISA, indicating a sensitivity of 100% and a specificity of 84% for the recognition of pancreatic cancer.
  • CONCLUSIONS: The detection of DJ-1 and HSP27 in pure defined tissue and the retrieval of HSP27 in serum by antibody-based methods identifies a potential marker for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Heat-Shock Proteins / analysis. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. Proteome / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303689.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


95. Yoong W, Subba B, Youssef I, Ojo K, Jarvis K: Pancreatic adenocarcinoma: a cause of elevated serum beta HCG. J Obstet Gynaecol; 2005 Jan;25(1):89-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: a cause of elevated serum beta HCG.
  • [MeSH-major] Adenocarcinoma / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Pancreatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16147719.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


96. Morganti AG, Calista F, Mignogna S, Macchia G, Deodato F, Scambia G, Carbone A: Synchronous male carcinoma of the breast, exocrine pancreas, and prostate. South Med J; 2008 May;101(5):567-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous male carcinoma of the breast, exocrine pancreas, and prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms, Male / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Prostatic Neoplasms / pathology


97. Casadei R, Monari F, Buscemi S, Laterza M, Ricci C, Rega D, D'Ambra M, Pezzilli R, Calculli L, Santini D, Minni F: Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg; 2010 Aug;62(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perioperative and outcome data were analyzed in two different groups: ductal adenocarcinoma (group 1) and non-ductal adenocarcinoma (group 2).
  • Twenty (16.9%) total pancreatectomies out of 118 pancreatic resections were performed.
  • Seven (35.0%) patients were affected by ductal adenocarcinoma (group 1) and the remaining 13 (65.0%) by pancreatic diseases different from ductal adenocarcinoma (group 2) [8 (61.5%) intraductal pancreatic mucinous neoplasms, 2 (15.4%) well-differentiated neuroendocrine carcinomas, 2 (15.4%) pancreatic metastases from renal cell cancer and, finally, 1 (7.7%) chronic pancreatitis].
  • Its indications are increasing because of the more frequent diagnose of pancreatic disease that involved the whole gland as well as intraductal pancreatic mucinous neoplasm, neuroendocrine tumors and pancreatic metastases from renal cell cancer.
  • [MeSH-major] Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845100.001).
  • [ISSN] 2038-131X
  • [Journal-full-title] Updates in surgery
  • [ISO-abbreviation] Updates Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


98. Koizumi M, Sata N, Shimura K, Tsukahara M, Yoshizawa K, Kurihara K, Hyodo M, Yasuda Y, Nagai H: [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
  • A 3 cm tumor was found in the head of the pancreas by abdominal CT, and the patient underwent laparotomy.
  • The tumor was histologically diagnosed as a well-differentiated adenocarcinoma, and showed extensive invasion to the portal vein (T4NXM 0 Stage IV a).
  • Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


99. Butte JM, Torres J, O'Brien A, Jarufe N, Llanos O: [Intraductal papillary mucinous neoplasm of the pancreas]. Rev Med Chil; 2008 Apr;136(4):517-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous neoplasm of the pancreas].
  • [Transliterated title] Neoplasia mucinosa intraductal del páncreas.
  • Intraductal papillary mucinous neoplasm of the pancreas is characterized by a dilatation of the main pancreatic duct and/or secondary ducts, mucin production and the absence of ovarian-like struma.
  • The symptoms are non-specific and often the diagnosis is incidental.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pancreatectomy. Pancreatic Ducts / pathology. Pancreatic Ducts / radiography. Pancreatic Ducts / ultrasonography. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769796.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 38
  •  go-up   go-down


100. Meyer JJ, Willett CG, Czito BG: Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma? Future Oncol; 2008 Apr;4(2):241-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?
  • Pancreatic cancer remains a highly challenging problem in oncology.
  • Radiation continues to play a role in the treatment of pancreatic cancer, in both the adjuvant and locally advanced settings.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / radiotherapy. Radiotherapy / methods






Advertisement